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Abstract
Mathematical modelling of hypoglycaemia and lactic acidosis in
the bloodstream of Plasmodium berghei infected rats: a feasibility
study
N. Walters
Department of Biochemistry,
University of Stellenbosch,
Private Bag X1, 7602 Matieland, South Africa.
Thesis: MSc (Biochemistry)
2016
Needless prescription and overuse of anti-microbial compounds served as a catalyst
for the evolution and rise of multiple drug resistant pathogens, one of humanities
greatest threats in the anti-biotic era. Resistance to our last line of defence drugs
for malaria, a disease that reportedly caused the deaths of more than half a million
people in 2013, is being reported in South-east Asia, necessitating the need for a
novel high throughput method of anti-malarial drug development. Advances in the
field of systems biology and further development of metabolic control analysis, could
be used to identify drug targets from metabolic models.
The purpose of this project was to investigate the feasibility of creating a whole
body model of rats infected with P. berghei. To assess the feasibility, a initiatory gly-
colytic model was constructed and the possibility of modelling the change in blood
parameters over the course of a malarial infection was investigated. Wistar rats were
infecting with P. berghei, ANKA strain, and blood parameters, including blood glu-
cose and lactate concentration, haematocrit and parasitemia was measured and the
relationship between the parameters evaluated. Furthermore, pulse experiments
were performed to analyse the possibility of modelling the homeostatic potential of
the rat. Microscopy and enzymatic glucose and lactate concentration determina-
tions proved to be reliable and accurate methods to measure blood parameters. In
addition, a relationship between parasitemia and the other blood parameters could
be quantified, providing evidence that the physiological changes during malarial in-
fection could be modelled. The glycolytic enzymes were liberated from the parasites
and biochemically characterized. The kinetic parameters obtained from the char-
acterization were subsequently used to construct a glycolytic model. Steady state
concentrations predicted by the preliminary model fall within physiological ranges,
3
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4 ABSTRACT
indicating that the model construction is feasible.
In conclusion, the results from the experiments, biochemical characterization of
the glycolytic enzymes isolated from P. berghei and preliminary model construction
of the glycolytic pathway supports the feasibility of creating a complete whole body
model, warranting further investigation.
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Chapter 1
General Introduction
One of humanities greatest obstacles of the 21st century is countering the emerging
multidrug-resistant diseases. The overuse and needless prescription of antibiotics
and other anti-microbial medicament served as a catalyst for the evolution of the
multiple-drug resistant organisms. Multiple-drug resistant Mycobacterium tubercu-
losis is of great concern, especially in third world countries where reliable medicine
is hard to come by(Johnston et al., 2009). Staphylococcus aureus, another infectious
pathogen, is rapidly gaining resistance to all anti-biotic classes, is becoming increas-
ingly difficult to treat(Enright et al., 2002). Immunocomprimised patients, those
with AIDS (acquired immune deficiency syndrome) and other immunocomprimising
diseases, are particulary susceptible to multiple-drug resistant S. aureus as it is a
opportunistic infections, most commonly found in hospitals (Archer, 1998).
According to the latest estimates of the World Health Organisation (WHO) re-
leased in December 2014, 584 000 deaths were caused by malaria infection in the
year 2013. Children are the most vulnerable to malaria and it is estimated that a
child dies every minute of malaria, predominantly in Africa (WHO, World Malaria
Report 2014). Malaria has plagued humans for millennia, but humans managed to
drive the disease to mainly equatorial countries with the discovery and use of qui-
nine (Peters et al., 1970). First reports of quinine resistance appeared in 1910 and
humans were forced to find a new anti-malarial drug and as a result, chloroquine, the
famous antimalarial drug, was discovered at Elberfeld Laboratories in 1934 (Coat-
ney et al., 1963). During the 1980’s, chloroquine resistance malaria arose across
Africa, Southeast Asia and South America, forcing, yet again, the drive for novel
drug development (Wernsdorfer and Payne, 1991). Sulfadoxine-pyrimethamine, a
cost-effective and efficient antimalarial drug discovered by Guttman and Ehrlich
(Carson, 1984), and mefloquine was discovered soon after and allocated as the first-
line of defence drugs for malarial treatment, but resistance to these drugs is present
today (Wongsrichanalai et al., 2002)(Miller and Su, 2011). Recent advancements
by the researchers at the University of Cape Town led to the discovery of a unique
antimalarial, 2-Aminopyridine MMV390048, drug which is still in pre-clinical trails
(Younis et al., 2014), but shows promise. History clearly tells a grim tale of the
rate of drug discovery being significantly slower than drug resistance evolution and
a new high throughput antimalarial drug development method is needed as the re-
sistance to our last-line-of-defence drug, the costly artemisinin, is being reported in
12
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Southeast Asia (WHO, World Malaria Report 2014).
Malarial infection has four conserved and distinct phases across all the different
Plasmodium species. An overview of the life-cycle is displayed in figure 1.1. The ga-
metocytes, the sexual forms of the parasite, fertilise in the midgut lumen of a female
Anophilese mosquito, producing zygotes that develop into motile ookinetes, altering
the status of the mosquito from non-communicable to infectious(Dimopoulos et al.,
1998). The motile ookinetes develop into oocysts and rupture, releasing motile
sporozoits, which infects the salivary glands. During a blood meal, the sporozoites
are injected into the bloodstream of the animal the mosquito is feeding on and, by
travelling through the bloodstream, reaches the liver and subsequently infects the
hepatocytes (Amino et al., 2006). The intracellular sporozoits differentiates to form
meroizoites, which are released directly into the blood stream to start the asexual
phase, also known as the blood stage, of the malarial life cycle (Sturm et al., 2006).
During the asexual phase, the merozoites invade red blood cells (RBCs), also known
as a erythrocyte, to replicate. Plasmodium berghei, the primary focus of this study,
selectively invades young reticulocytes (affinity 150-fold greater compared to mature
RBCs), complicating growing the organism in vitro (Cromer et al., 2006). During
the blood stage, the parasites consumes nutrients through the parasitophorous vac-
uole membrane by means of highly efficient transporters as well as metabolising the
haemoglobin molecules within a vacuolar compartment known as a digestive vac-
uole, excreting toxic heme crystals as detoxified hemozoin in return (Wunderlich
et al., 2012). The merozoites develop into rings, trophozoits, schizonts and lastly,
differentiates into merozoites again. The time it takes to complete a full blood life
cycle, namely from merozoite to merozoite again, differs between the Plasmodium
species.
Figure 1.1: The diagram represents the conserved life cycle of Plasmodium taken from
Winzeler (2008). The full description of the life cycle is discussed in the text.
The protozoans responsible for world wide human malaria include Plasmodium
falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malaria. P. fal-
ciparum is responsible for 80% of malarial cases and responsible for 90% of malarial
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related deaths, but recently, another human malaria has been discovered, Plas-
modium knowlesi, with a life cycle closer to P. berghei, a murine malaria, than P.
falciparum (Manguin et al., 2010). The other murine malaria parasites include P.
chabaudi, P. vinckei and P. yeolii, but P. berghei has been used as a popular model
organism due to the ease of genetic engineering (Craig et al., 2012).
Great improvements have been made in the field of antimalarial drug develop-
ment in recent years: Fortuitous discoveries of drugs in the past has been replaced
with side chain alterations to increase effectiveness or circumvent resistance. The
increased need for novel drugs led to the development of improved drug design using
side-effect similarity (Campillos et al., 2008). The nature of organisms to inexorably
gain resistance to our novel drugs resulted in the exploration of soft drug design.
The aim of this approach was to develop safer drugs by considering the effects of
the metabolism when creating metabolites that inactivate enzymes to elicit a ther-
apeutic response (review by Bodor and Buchwald (2000)). Discoveries in the the
field of integrated metabolic modelling and analysis opened up new possibilities to
find weaknesses in organisms. By performing metabolic control analysis (MCA),
an enzyme that dominates the flux could be identified and exploited (Snoep et al.,
2015). The combined work of Gerald Penkler, Francois du Toit and Francois Brand
from the Molecular and Systems Biology lab at the University of Stellenbosch cre-
ated a combined working model for the metabolism of P. falciparum and the human
RBC, that lead to the successful identification of a potential drug target, namely
the parasitic hexose transporter (Snoep et al., 2015).
The goal of this thesis was to test the feasibility of creating a whole
body model capable of describing the progression of the malarial infec-
tion and it’s effect on the body’s physiological state on a metabolic and
biochemical level. The feasibility of the model will be measured by the ability
of the model to predict the intercellular concentrations of the metabolites and the
flux of the glycolytic pathway. For this research project, rats were infected with P.
berghei to test the feasibility of creating a model that could potentially describe the
metabolic changes resulting from the infection. A basic model had to be constructed,
but to do so the following objectives had to be completed:
1. Infect Wistar Rats with P. berghei, ANKA strain, and obtain blood glucose
and lactate data for the progression of the malarial infection whilst measuring
the ability of the rat to maintain homoeostasis of the blood glucose and lactate
after incurring small perturbations
2. Isolate the parasites from the RBCs and subsequently lyse the cells to free the
enzymes.
3. Measure the kinetic parameters of the intercellular enzymes of the P. berghei
parasite
4. Use the kinetic parameters of the different enzymes to produce a working
model of the glycolytic pathway
The outcomes of the objectives will be discusses in the three research chapters.
Each chapter will contains introduction, methods and materials and results and
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discussions sections for the respective experiment and outcome. Chapter 2, entitled
"Rat blood analysis", will discuss the infection of the rats, the obtaining of the blood
glucose and lactate, the pulse experiments, the measuring of the blood glucose and
lactate, parasitemia and haematocrit measurements and the results obtained from
the measurements. In chapter 3, "Enzymes kinetics", the method of extracting the
enzymes as well as performing the enzyme kinetic studies will be discussed. The
introduction and methods and materials for chapter 3 include detailed information
on enzyme isolation, the enzymes in question and enzyme characterization. Results
of the enzyme characterization is discussed at the end of chapter 3. Metabolic model
construction is covered in chapter 4, named "Model creation". The methods for the
model creation is discussed along with the equations used for the glycolytic model.
Finally, the thesis concludes with a discussion chapter, chapter 5, which will discuss
the feasibility of the model and the possibility of creating a full body model and the
requirements thereof.
Stellenbosch University  https://scholar.sun.ac.za
Chapter 2
Rat blood analysis
2.1 Introduction
In this study, we attempt to assess whether creating a whole body model is feasible.
The feasibility would depend on our ability to measure different blood parameters
our ability to fit rate equations to the kinetic data sets to adequately describe the
perturbations the malarial infections would make to the normal blood values of a
rat. Should such a study prove possible, a model could be created and adjusted for
human anatomy to be used as a drug target identification or a diagnostic tool.
Ultimately, the goal of the rat studies was to create a whole body model that is
capable of mathematically predicting the change in blood glucose and lactate levels
based on kinetic values of the rats’ blood glucose and lactate homeostatic potential
and the malarial parasites’ use of nutrients in the blood. Such a model could be
used to determine the extent of infection. Combining a detailed kinetic model of
the metabolisms of the malarial parasite and red blood cell could potentially lead
to the uncovering of a weakness in the malarial parasite. To identify a weakness,
metabolic control analysis needs to be performed to identify the enzymes with the
dominant control over the system’s flux whilst being sufficiently different from the
RBCs homologues enzyme. Figure 2.1 displays a simplified diagram that describes
the changes in blood glucose and lactate as a result of the rat’s and the malarial
parasite’s metabolisms. Equation 2.1 and 2.2 forms the foundation for the simplified
model adapted from Sorensen (1985) with λ being the body’s ability to produce, p,
or consume, c, glucose or lactate and  the malarial parasite’s ability to consume
glucose and produce lactate.
dglu = λglu·p − λglu·c − c (2.1)
dlac = λlac·p − λlac·c + p (2.2)
The above equations could be dissected further to include the parameters that
change the production and consumption rates of both the malaria parasite’s and
body’s metabolisms. The resting glucose consumption of a body is influenced by
the insulin-blood glucose ratio, whilst the body’s resting production of glucose is de-
pendent on the insulin concentration and the basal glucose production rates (Parker
16
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et al., 1999). Both the glucose production and glucose consumption rates are in-
fluenced by the haematocrit with lower haemoglobin concentrations increasing the
glucose turnover rate (Henderson et al., 1986). Resting lactate production and con-
sumption rates depend on the body’s basal rates as well as the oxygen concentration
in the blood. Malarial consumption of glucose and production of lactate would pre-
dominantly depend on the parasitemia (parasites per RBC in the blood), glucose
concentration in the blood and oxygen concentration in the blood (Bowman et al.,
1960). For simplification of this study, it is assumed that the malaria parasites only
utilizes anaerobic glycolysis and would produce 2 units of lactate per unit of glucose
consumed.
Figure 2.1: Simplified schematic of influences of blood glucose and lactate. The schema
portrays a simplified view of the metabolism of the body that removes lactate or glucose
from the blood and converts it to glucose and lactate respectively. The malaria parasite
utilizes glucose as a carbon fuel source and converts the sugar to lactate in the blood.
The first set of experiments was to test the feasibility of measuring changes in
the blood, which include the parasitemia, the haematocrit (amount of RBCs per
unit volume of whole blood (unaltered blood)), blood glucose and blood lactate
concentrations. During the course of the infection, parasitemia would be expected
to increase exponentially as one parasite could release multiple merozoites to reinfect
more RBCs and continue the asexual cycle of malaria. The exponential growth, as
with all parasitic organisms, would be dependent on the abundance of nutrients, the
growth conditions, the influence of the host’s immune system and the availability
of cells to infect. Since P. berghei infects and ruptures murine RBCs, one would
expect to see an increase in the amount of parasites in the blood, but a decrease
in the amount of RBCs. Because of the rupturing of the RBCs, the haematocrit
should decrease proportionately to the increase of the parasitemia if no other RBCs
are created. The rate of increase of parasitemia per day could therefore be calculated
if the rate of haematocrit decay is known. The proportionality of parasitemia and
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haematocrit was tested in this study to see if it is feasible to create a model that
could describe the growth of the parasite along with the decay of the RBCs.
Malaria, being a voracious consumer of glucose to produce lactate, is known for
causing lactic acidosis (acidifying of the blood by introduction of excessive amounts
of lactate into the blood) (Holloway et al., 1995). The increase in blood lactate
and decrease in blood glucose could indicate the extent of the malarial infection
(parasitemia)(Holloway et al., 1991). The relationship of blood glucose and blood
lactate was then tested in this thesis to assess if creating a mathematical model
could describe the changes in the blood concentrations and the parasitemia.
Changes in blood glucose and lactate is not only dependent on the parasitemia,
but also the body’s ability to maintain homeostasis. Homeostasis is regulated by a
complex network of organs and hormones and could prove too complex to describe
mathematically, but for this study, we set out to access the feasibility of measuring
the homeostatic potential of the rat’s metabolism by perturbing the blood glucose
and lactate concentrations and measuring the time it took for the metabolism of
the rat to return the blood concentrations to normal. The extent of the infection
could influence the rat’s homeostatic potential, from the acidifying of the organs
and increased glucose turnover rate from the increase in parasites, which could be
modelled mathematically (Haque et al., 2011). The model would then be capable of
predicting the changes in blood glucose and lactate as a function of the parasitemia.
The aim of this chapter was to investigate the feasibility of the above mentioned
potential relationships. To test this, we looked at the possibility of measuring the
parasitemia and haematocrit. The relationship between the two variables was then
scrutinized. Blood glucose and lactate determination was then investigated and the
correlation between the concentrations and the parasitemia analysed. Should all the
experiments conclude that the relationships could be described mathematically, the
creation of a mathematical model would be deemed plausible and the feasibility of
the study warrants further investigation.
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2.2 Methods and Materials
2.2.1 Materials
For increased accuracy and consistency, all the chemicals used in the experiments
were purchased from Sigma-Aldrich unless otherwise stated in text. ANKA strain
malaria was obtained from Grootte Schuur hospital in Cape Town and the rats were
obtained from Stellenbosch university, Tygerberg campus.
2.2.2 Ethical Clearance
Ethical clearance to perform the study on rats was obtained on the 24th of August
2013, along with Biohazard clearance, from the faculty of health sciences animal
research ethics committee, University of Cape Town (Application 014/006).
2.2.3 Innoculation and acquisition of the rats
A summary of the experimental design is displayed in figure 2.2. Albino Winstar
rats, aged 5-6 weeks, with a mean body mass of ±200 g were purchased from Tyger-
berg Hospital in Bellville, South Africa. Older rats seem to not be aﬄicted by
malarial infection after inoculation. The rats were given 3 days to acclimatize to
the new environment. On the last day of acclimatization, blood was drawn from
the rats’ tails to measure the basal blood glucose and lactate concentrations as well
as the haematocrit. 15 rats were inoculated with 1× 106 P. berghei, ANKA strain,
into the penile vein, slightly less than the amount found to cause 100% mortality
(Pedroni et al., 2006). The inoculate was drawn from 2 donor rats that were infected
prior to the start of the experiment.
2.2.4 Daily blood sampling
During the course of the experiment (day 2 till day 12), blood was drawn from
the rats daily. A small tube was used to trap the rats to simplify drawing ±200
µl of whole blood from the tail of the rats using a 21 gauge needle. Whilst the
wound still bled, blood from the needle wound was applied to a clean microscope
plate for parasitemia measurements. 20 µl of the drawn whole blood was aliquoted
into a separate tube along with 5 µl anticoagulant, CPDA fluid (Appendix A),
for haematocrit measurements. The remaining blood was then centrifuged using a
desktop centrifuge (Prism Mini centrifuge, 2000 × g) for 1 minute and two sets of
50 µl plasma supernatant were removed and placed in different tubes for separate
lactate en glucose concentration determinations. All the rats were euthanised 12
days post inoculation to minimize animal suffering.
2.2.5 Determining parasitemia with microscopy
During the daily blood collection, a drop of blood from the syringe of each infected
rat was placed on a microscope slide and smeared. After the blood smear was
completely dry, the blood was fixed by inundating the slide with methanol for 30
seconds. The methanol covering the slide was then washed away with water and
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Figure 2.2: Experimental design for the in vivo rat study. The figure graphically describes
the course of the experiments done on the rats. The total duration of the experiment was
12 days, starting with 30 uninfected rats of which 15 were inoculated with P. berghei and
15 kept as a control group. The different elements of the flow chart describe the events of
the different days.
dried. Diluted (1:9 in PBS) Giemsa’s stain solution (Merck (Pty) Ltd, Germany)
was used to cover the fixed smear for approximately 10 minutes. The Giemsa’s stain
was washed off with water and completely dried before viewing the slide under a
microscope. Three different photos were taken of each slide for counting. Percentage
parasitemia was calculated by counting the total number of RBCs in the photos,
counting the total number of parasites, including multiple parasites per RBC, and
dividing the amount of parasites with the total number of RBCs.
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2.2.6 Determining haematocrit with microscopy
The 25 µl samples of each rat drawn daily, consisting of 20 µl whole blood and 5 µl
CPDA fluid, was diluted (1:1). From the dilute, ±10 µl is injected into a Marienfeld
improved Neubauer counting chamber and placed under a microscope for counting.
Total intact RBCs from 5 inner haemocytometer counting chambers was counted.
The average from the 5 counts was then used as the haematocrit of the rat on that
day post inoculation.
2.2.7 Blood glucose concentration determination
Daily blood glucose concentration of each rat was determined enzymatically using
a BioTek Powerwave 340 spectrophotometer. A glucose determination cocktail was
created for the measurements, which contained 2.5 mg/ml adenosine triphosphate
(ATP), 0.5 mg/ml nicotinamide adenine dinucleotide phosphate (NADP+) and 10
µl/ml HK/G6PDH (hexokinase/glucose-6-phosphate dehydrogenase mixture), link-
ing enzyme, in glucose-lactate determination buffer (GLDB, Appendix A). In a well
of the microplate, greiner 96-well plate, 5 µl of 1:1 diluted sample or glucose standard
(0 - 10 mM used as a internal standard) was added with 95 µl of glucose determina-
tion cocktail and the absorbance measured at 340 nm with the spectrophotometer
after a 15 minute incubation at room temperature. All samples were measured in
triplicate.
2.2.8 Blood lactate concentration determination
Blood lactate concentrations from each infected and uninfected rat was determined
enzymatically using a BioTek Powerwave 340 spectrophotometer. A lactate de-
termination cocktail was created for the measurement, which contained 40 µl/ml
Hydrazine, 4 mM NAD+ and 2 µl/ml lactate dehydrogenase (LDH), as linking en-
zyme, in GLDB (Appendix A). In a 96 well Greiner plate, 5 µl of sample or lactate
standard (0 - 20 mM) was added with 95 µl of the lactate determination cocktail.
The plate was incubated for 90 minutes at room temperature and kept away from
light contact before placing it in the spectrophotometer to measure the absorbance
at 340 nm. All samples were measured in triplicate.
2.2.9 Pulse experiments
On day six post inoculation, the pulse experiments were performed. Of the 15 rats,
3 groups of 5 rats each were used from both the infected and uninfected rats for
the pulse experiments. The 3 groups were injected with either saline solution, 1.3
mmol/kg body weight glucose or 0.64 mmol/kg body weight lactate. To increase
the accuracy of the experiments and to minimize suffering of the animals, the ani-
mals were anaesthetized with 4% isoflurane during the experiment. Blood sampling
(50 µl per sampling) was drawn before the injection, 2, 5, 10 and 30 minutes af-
ter the injection. The whole blood sample was then centrifuged using a desktop
centrifuge (Prism Mini centrifuge, 2000 × g) for one minute. A 20 µl supernatant
was then removed and aliquoted into two tubes; 10 µl per aliquot for glucose and
lactate determination as outlined above. Deviating from the standard blood glucose
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and lactate determinations described in this section, the samples were measured in
duplicate.
2.2.10 Computational analysis and statistics
The enzymatic and microscopical data obtained were interpreted using GraphPad
Prism version 5.0 and the statistical analysis performed with the same program.
The graphs were produced with Wolfram Mathematica version 10.0.
2.3 Results and Discussion
2.3.1 Parasitemia
The first set of experiments was conducted to assess if measuring the parasitemia
is possible and if an equation could be fitted to the rate of increase in parasitemia
over the course of the infection. Considering a full blood cycle of a RBC infected
with a single merozoite could release between eight and sixteen merozoites, expo-
nential growth is expected to be observed during the course of the infection (Killick-
Kendrick, 1974). An example of the photos taken from the slides as well as the
progression of the malarial infection is given in figure 2.4. Figure 2.3 A shows the
results from the average parasitemia measurements as a function of time in days
and an exponential curve can be observed. Using the log of the average parasitemia,
Figure 2.3 B, as a function of time (day) a linear correlation (p < 0.0001) is observed.
From the logarithmic linear growth curve, a doubling time of 1.98 days is calculated,
but true growth modelling is too complex for this thesis, as the growth is dependent
on numerous factors (discussed later in this thesis). The elements that could be
responsible for the lower than expected growth rate include a sub-optimal growth
if a RBC is infected with multiple merozoites, selectivity for immature eurythro-
cytes, immune system counteracting the growth, the creation of more erythrocytes
and the time-dependent loss of invasive ability of the merozoites (McAlister (1977),
Bannister et al. (1975)). The full set of parasitemia measurements for all the rats
is displayed in figure B.1. The full data set shows that the rate of increase in par-
asitemia is variable between the rats and that an average of the parasitemia is a
better measuring tool for model creation.
2.3.2 Haematocrit
The rupturing of the RBCs to release the merozoites during the asexual blood cycle
could lead to a decrease in the total haematocrit of the rats. The haemtocrit of the
infected rats were measured to assess the feasibility of finding a correlation between
the increase in parasitemia and haemtocrit. Average haematocrit of all 15 infected
rats is displayed on figure 2.5 with graph A depicting the average haematocrit as a
function of time (days). A linear correlation (p < 0.01) exists between the decline
of the haematocrit and course of the infection (line not shown). Figure 2.5 B shows
the average haematocrit as a function of the log of the average parasitemia. Another
linear correlation (p < 0.01) exists between the average haematocrit and the log of
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Figure 2.3: Results from the parasitemia measured represented as average parasitemia over
the course of the infection. The two graphs represent the average parasitemia of the rats
per day (A) and the log of the average parasitemia of the rats (B) per day post inoculation.
The average parasitemia shows a clear exponential curve which is confirmed by fitting a
straight line to the log of the average parasitemia (p < 0.0001). The full set of parasitemia
values are given in figure B.1 for both the average parasitemia and the log of the average
parasitemia.
the average parasitemia (line not shown). A true mathematical relationship between
parasitemia and haematocrit is too complex to equate in this thesis, but a linear
correlation for both graphs is statistically true. The change in haematocrit could
be studied further by including the body’s ability to create new RBCs and by sepa-
rating the reticulocytes from the eurythrocytes to study the effect of the preference
for immature RBCs and to create a model for the change in haematocrit during the
course of an infection (Janse and Waters, 1995). A haematocrit minimum of ±20%
was observed in 2.5. If the haematocrit decreased any further, it would result in
the death of the rat. Measuring the haematocrit could therefore serve as a viable
diagnostic tool to measure the extent of the malarial infection and could lead to a
method to prioritise the healthcare of critically ill malaria patients if a mathematical
relationship exists between haematocrit and other blood parameters (parasitemia,
blood pH, blood glucose concentration ect.). The full set of haematocrit measure-
ments for all the rats is displayed in figure B.2 in appendix B. The full data set does
not provide any further insight into rate at which the haematocrit decreases during
malarial infections.
2.3.3 Blood glucose and lactate
A validated and working full body model would be able to predict the changes of
blood glucose and lactate during the course of the infection. Since P. falciparum
consumes glucose at a rate of between 50 and 100 times that of uninfected human
RBC, it could be assumed that P. berghei will follow a same trend (Roth Jr, 1989).
We set out to assess if measuring the blood glucose and lactate concentrations is
possible and to find a link between the concentrations and parasitemia. High par-
asitemia would be expected to lead to a lower blood glucose concentration and an
increased blood lactate concentration as the 60 to 70% of glucose is converted to lac-
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Figure 2.4: Blood slides of a rat over the course of the infection. An example of the blood
slides taken each day, represented by the numbers next to the pictures, is displayed in this
figure. Counting the parasites, coloured blue by Giemsa’s stain, in the RBCs and dividing
by the total amount of RBCs in the slide gives an approximate parasitemia for the rat.
tate and transported out as lactate (Jensen et al., 1983). A study done by Holloway
et al. (1995) shows that a rat’s body is able to maintain nominal homeostasis for
lower concentrations of parasitemia, but after a certain threshold (±20%), the blood
glucose concentration decreases to a minimum of ±2mM and blood lactate increases
to ±12mM. Results from this project show a similar trend to that of the study with
regards to the decrease of blood glucose and blood lactate, displayed in figure 2.6,
but several differences are evident from the data obtained. Plotting the blood lac-
tate concentration as a function of the log of the parasitemia, Figure 2.6 A, does
not convey a clear correlation between the concentration of the blood lactate and
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A B
Figure 2.5: Results from the haematocrit measurements represented as average haema-
tocrit over the course of the infection. The average haematocrit over the course of the
infection is displayed as a function of days post inoculation (A) and log of the average
parasitemia (B). As expected, the haematocrit decreased over the course of the infection,
reaching a minimum of ±20% haematocrit. Lowering the haematocrit any further, would re-
sult in the death of the rat. A full set of haematocrit measurements for each rat represented
as both a function of time and parasitemia is displayed in figure B.2.
the extent of the infection. When blood lactate is plotted against the parasitemia
interval (intervals of 10%), Figure 2.6 C, the influence of parasitemia becomes more
visible with low blood lactate concentration at low of parasitemia (20% to 30%) and
great increases in blood lactate concentration above 60% parasitmeia. The reason
for the initial decrease in blood lactate could be a result of the adaptation of the rat’s
body’s metabolism to prioritize lactate consumption as there is a constant influx of
lactate from the parasites. The decrease in blood glucose concentration, Figure 2.6
B, shows a linear correlation (P < 0.0001 significantly non-zero slope) when plotted
against the log of the parasitemia. Figure 2.6 D does not show a clear correlation
between the interval of parasitemia (intervals of 10%) and the blood glucose con-
centration, but it should still be noted that higher concentrations of parasitemia of
greater than 40% has a lower blood glucose than the blood glucose concentration
of uninfected rats. A possible reason for the large variation in concentrations could
be due to the panicked state in which the animals presented themselves whilst the
blood was drawn. Future studies may necessitate anaesthesia for all the interactions
with the rats to increase accuracy of the experiments. Another valuable tool to be
used for the change in blood glucose and lactate levels could include the measuring
of the blood pH as the amount of lactate in the blood correlates to the acidifying of
the blood, since it has been reported that blood pH go down to as low as 6.98 from
7.23 in mice with 86% parasitemia (Kruckeberg et al., 1981).
2.3.4 Pulse Results
Construction of a whole body model requires knowledge of the homeostatic poten-
tial of rats body. The aim of this experiment therefore to assess the feasibility of
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Figure 2.6: Blood glucose and lactate concentrations over the course of the infection
displayed as a function of parasitemia and parasitemia interval (% parasitemia). The blood
lactate (A) and glucose (B) concentration (mM) for the infected rats is shown as a function of
the log of the different parasitemia’s for the rats. The lactate concentration does not show a
clear correlation to the log of the average parasitemia, while the blood glucose shows a linear
correlation (p < 0.01) to the log of parasitemia. The glucose concentration for the different
parasitemia intervals (D) does not show a clear correlation, but the lactate concentration (C)
for the different intervals shows an increase with high parasitemia intervals. Data could not
be obtained for the blood lactate concentration between the interval 50 to 60% parasitemia.
The full data sets for each rat is shown as a function of parasitemia (figure B.3) and day
post inoculation (figure B.4) in Appendix B.
measuring the homeostatic potential by perturbing the blood glucose and lactate
levels by performing pulse experiments. The glucose pulse experiments for both the
infected and the uninfected rats (figure 2.7 A and B respectively) displayed a classic
one phase decay curve over a period of time, returning to nominal blood glucose
concentrations after ±30 minutes (P < 0.01 for the uninfected rat glucose pulse)
similar to the results of Tsutsu et al. (1989). Both the lactate and glucose pulse
experiments did not yield any definitive influence by the infection, as no significant
differences can be observed between the infected and uninfected rat glucose pulse
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Figure 2.7: Blood glucose and lactate concentration from the pulse experiments for the
infected and uninfected rats. The data from the glucose pulse experiments for both the
infected (A) and uninfected (B) rats is shown as a function of time (minutes). Closed circles
represent the blood glucose concentrations and open circles the blood lactate concentrations.
A one phase decay is fitted to both graphs for the glucose concentration and a straight line is
fitted to the lactate concentration. The data from the lactate pulse experiments for both the
infected (C) and uninfected (D) rats is shown as a function of time (minutes). No discernible
correlation could be seen from the lactate pulse experiments.
experiments. The lack of correlation could be due to the low parasitemia (average
of 9.55% parasitemia) during the pulse experiments. Using a higher parasitemia,
larger variation in the parasitemia or a range of glucose concentrations could lead
to a better understanding of the homeostatic potential of the rat’s metabolism.
During the glucose pulse experiment, the blood lactate concentration did not seem
to change significantly which could be due to the parasitemia not being adequate
to convert significant amounts of glucose to lactate. No conclusions can be drawn
from both the infected or uninfected lactate pulse experiments displayed in figure
2.7 C and D respectively. Blood glucose concentrations remained largely unchanged
during the experiments, whilst lactate seems to increase during the course of the
lactate pulse. The reason for the increase in blood lactate concentration could be
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due to overcompensation of lactate removal, but the true reason is not known. One
conclusion that can be drawn for both the glucose and lactate pulse experiments is
the need for repeats of these experiments with higher parasitemia, ideally ± 50%,
to reach more definitive results. Since this study is on the feasibility of creating
a whole body rat model, the glucose pulse experiment was successfully performed,
suggesting that such a pulse experiment is possible and could provide researchers
with valuable information on the homeostatic capabilities of the rats.
2.3.5 Summary
The measuring of parasitemia, haematocrit and blood glucose and lactate was suc-
cessfully. Furthermore, a relationship between the different parameters was identi-
fied in this chapter, providing evidence that the construction of a whole body model
is feasible. Since we could determine exponential decay back to starting blood glu-
cose concentrations, the glucose pulse experiments proved successful. Interestingly,
there was no increase in the blood lactate concentrations after the glucose pulse
and the glucose consumption in infected and non-infected rats were very similar.
The lactate pulse was not so successful, since no increase in lactate was observed
immediately after the pulse. This could be due to having used too small a concen-
tration of lactate, or due to a very rapid lactate consumption rate. Strategies to
improve on the pulse experiment includes performing the experiment with a range
of pulse concentrations and performing the pulses at a larger parasitemia. Since the
blood analysis proved feasible, the possibility of constructing a metabolic model was
investigated for a complete whole body model in chapters 3 and 4.
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Enzymes kinetics
3.1 Introduction
A model that is only capable of describing the physiological response to an increase
in parasitemia lacks the depth needed to describe the influences of the metabolism
of the malarial parasite and the enzymes making up the different metabolic path-
ways. Metabolic models have been constructed for different organisms, including
S. cerevisiae and P. falciparum (Teusink et al. (2000), Snoep et al. (2015)). The
constructed models were not only capable of predicting the flux and steady state
metabolite concentrations, but were also capable of describing the effect inhibiting
one enzyme would have on the system as a whole, serving as a viable tool for drug
target identification. To create a model, the mechanism (kinetic parameters) of each
enzyme needs to be quantified in terms of the velocity with which each enzyme could
catalyse reactions in the system. Once the kinetic parameters are quantified, the
different enzymes could be combined to create a model.
Research done on Plasmodium spp. showed that, although many of the biosyn-
thesis pathways are omitted in the parasites, the core conserved metabolic path-
ways remain, including glycolysis, the pentose phosphate pathway, lipid biosynthesis
and parts of the tricarboxylic acid cycle (TCA) (reviewed by Olszewski and Llinás
(2011)). The majority of the auxiliary metabolic pathways, exluding glycolysis, are
found to form part of biosynthesis and not catabolism. The apparent inability of
the auxiliary pathway to perform catabolism could be due to the over abundance of
resources, both from the blood serum, glucose, and the breakdown of haemoglobin
from the RBCs to produce amino acids.
Since between 60 and 70% of glucose is converted to lactate, the remaining
glucose is presumed to flow into the pentose phosphate pathway (PPP) (Jensen
et al., 1983). Atamna et al. (1994) found that infected RBCs have PPP activity 78
times greater than that of the uninfected RBCs and the parasite has a PPP activity
24-fold greater than that of the RBC, which serves as affirming evidence that the
PPP is essential for the survival and growth of the parasite. Two major reasons
for the use of the PPP is the production of NADPH via the oxidative branch, used
to combat oxidative stress, and the creation of ribulose-5-phosphate for use in the
purine metabolism to synthesise nucleotides (Roth Jr et al., 1986). Degradation of
haemoglobin releases reactive oxygen species, including H2O2 and free haem, which
29
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causes oxidative stress (Becker et al., 2004). Reduced glutathione (GSH) is used to
reduce the oxidative radicals which in turn creates oxidized glutathione disulphate
(GSSG). GSH thus offers oxidative protection for both the RBC and the parasite.
NAPDH, produced from the PPP, is used as reducing agent to reduce GSSG and
restore the GSH balance. The non-oxidative branches uses fruktose-6-phosphate
(F6P) and glyceraldehyde-3-phosphate (GAP) from from glycolysis as the substrates
to be converted to sedoheptulose-7-phosphate and erythrose-4-phosphate.
Although the malarial genome contains all the genes encoding for mitochondrial
enzymes, the role of the enzymes aren’t well understood (Fry and Beesley, 1991).
The creation of acetyl-CoA, via purine salvage pathway mediated by the tricar-
boxylic acid (TCA) cycle used in lipid metabolism, appears to be the purpose of the
expressed TCA enzymes in Plasmodium(reviewed by Van Dooren et al. (2006)). The
asexual stage malarial parasite lacks the enzyme pyruvate dehydrogenase needed to
convert pyruvate to acetyl-CoA to initiate the TCA cycle (Pei et al., 2010). Ox-
aloacetate, an intermediatary step for the interconversion between aspartate and
malate, is formed via phosphoenol pyruvate (PEP) carboxylase and could influence
the total amount of lactate produces by siphoning PEP away as part of a carbon
fixation pathway (McDaniel and Siu, 1972). For the purpose of this study, the TCA
cycle and PEP decarboxylase were assumed to not influence the use of glucose or
production of lactate.
Investigating the feasibility of measuring the velocity and calculating the kinetic
parameters of the glycolytic enzymes was the focus of this chapter. The aim was
to characterize all 11 enzymes in the glycolytic pathway of P. berghei. Substantial
proof for the feasibility of creating a model will exist if the characterization of the
enzymes are possible.
3.1.1 Kinetic parameter quantification
A simplified schema of the glycolytic pathway is presented in figure 3.1. Glucose
is converted to lactate by 11 enzymatic steps. Plasmodium spp. lacks the enzymes
necessary to undergo gluconeogenesis, except for phoesphoenolpyruvate carboxyki-
nase, which is thought to be used for carbon fixation (Hayward, 2000). The analysis
of the enzymes involved measuring the different specific activities (maximal velocity
of the reaction normalised to protein concentration) for different substrate, product
and inhibitory concentrations. Michealis-Menten equations are needed to describe
the change in specific activity of the enzymes (Atkins and Nimmo, 1975).
S V1−−→ X V2−−⇀↽− P (3.1)
The simplified reaction (eq. 3.1) illustrates a simple reaction where a substrate,
S, that is converted to metabolite, X, and then converted to product, P. The conver-
sions are done in two steps, named v1 and v2 , which can be adapted to equate the
rate at which X is produced or consumed. The rate of the irreversible first reaction,
v1, could be quantified with a standard irreversible Michaelis-Menten equation (eq.
3.2) (Goudar et al., 1999). A reversible reaction, eg. v2, requires the incorporation of
both the forward, Vf , and reverse, Vr, maximal velocities into the standard uni-uni
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Michaelis-Menten reaction (eq. 3.3). The reactions could be expanded to include
substrate, product and allosteric inhibition.
v1 =
Vmax · [s]
Ks + [s]
(3.2)
v2 =
Vf
[x]
Kx
− Vr [p]Kp
1 + [x]Kx +
[p]
Kp
(3.3)
Without purifying the different glycolytic enzymes, some of the enzymes could
not be measured in either the forward or reverse direction. The limitation of max-
imal rate measurements was circumvented by using the Haldane relation (eq. 3.4)
(Mellors, 1976). For a reaction to reach equilibrium, the forward and reverse reac-
tion must be equal and, if the Keq is known, the maximal velocity of the missing
parameter could be substituted using the Haldane relation. All the enzymes were
characterised in enzyme assay buffer (EAB, Appendix A) at a pH of 7.17 that resem-
bles intracellular conditions. EAB does not necessarily allow for maximal activity
of the enzyme, rather, a physiological activity.
[p]eq
[x]eq
= Keq =
VfKp
VrKx
(3.4)
3.1.2 Glycolytic enzymes
3.1.2.1 Hexokinase
Hexokinase (HK, EC 2.7.1.1) catalyses the important first step in glycolysis to start
the catabolism of glucose. The enzyme, also called ATP:D-hexose 6-phosphotransferase,
transfers a phosphate from ATP to glucose to create ADP and glucose-6-phosphate
(G6P). The HK from P. Berghei catalyses the reaction 35 times faster than normal
uninfected mouse erythrocytes (Kumar and Banyal, 1997). Like most of the Plas-
modium glycolytic enzymes, HK is coded on one gene with no isoenzymes during
the asexual phase, which could be the reason for the improved functionality of the
parasitic enzyme compared to the mammalian orthologue (Olafsson et al., 1992).
Kumar and Banyal (1996) biochemically characterised the 47 kDa P. berghei en-
zyme in cell-extract and found that HK has a ATP Km of 2mM and 0.431mM for
glucose. Although P. berghei can only use glucose as a hexose substrate, Sherman
(1979) found that some species of Plasmodium can use other hexose sugars, specif-
ically mannose. The reaction is considered to be irreversible, although Wiser and
Schweiger (1985) reported that glucose-6-phosphatase concentration increases with
maturation of P. vinckei which could convert glucose-6-phosphate (G6P) back into
glucose.
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Figure 3.1: Simplified schema of glycolysis used to create the glycolytic model. The schema
represents the classic view of glycolysis where glucose is converted to lactate by means of
11 enzymatic reactions. The shape of the different metabolites and enzymes represents the
different roles in the model with the square representing a constrained metabolite, diamond
an enzyme catalysed reaction and a circle represents a variable metabolite.
3.1.2.2 Glucosephosphate isomerase
Isomerization of G6P to fructose-6-phosphate (F6P) is catalysed by glucosephos-
phate isomerase (GPI, EC 5.3.1.9). Srivastava et al. (1992) purified the 66 kDa
enzyme and found that P. falciparum has 3 or 4 isoenzymes which confers a 4 to
9 times greater GPI activity than uninfected RBCs. Inhibition of the enzyme has
no effect on the host GPI, indicating that substantial differences exist between host
and Plasmodium enzyme structure (Srivastava et al., 1992).
3.1.2.3 Phosphofructokinase
The creation of fructose-1,6-bisphosphate (F16BP) and ADP from F6P and ATP is
catalysed by phosphofructokinase (PFK), a key-regulatory enzyme in the glycolytic
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pathway (Buckwitz et al., 1990a). Extensive differences exist between the Plas-
modium PFK and the erythrocytic native PFK. The different allosteric activation
molecules is one of the major differences with erythrocytic PFK being activated by
fruktose-2,6-biphosphate and AMP whilst Plasmodium spp. PFK is activated by
PEP, F6P and Pi, while only being marginally activated by AMP (Jacobasch et al.,
1989). According to Buckwitz et al. (1990a), non-allosteric inhibition, as well as
Mg-ATP binding site, competitive inhibition is observed with the addition of ADP;
Furthermore, Buckwitz et al. (1988) observed increased inhibition of PFK by ATP
with a decrease in pH. Buckwitz et al. (1990b) went further and described the effects
of Mg-ATP, free ATP and Mg2+ on the activity of PFK and found that, whilst an
increase in the substrate (Mg-ATP) does not inhibit the reaction, free ATP and
Mg2+ inhibit the reaction allosterically. The size, structure and genetic code of the
enzyme have yet to be elucidated.
3.1.2.4 Aldolase
The aldol-cleaving of F16BP to form dihydroxyacetone phosphate (DHAP) and
glyceraldehyde-3-phosphate (GAP) is mediated by fructose-1,6-bisphosphate aldolase
(ALD). Fructose-1-phosphate is cleaved by ALD as well but at a slower rate than
F16BP. Two virtually identical ALD isoenzymes exist, ALD-1 and ALD-2, but ALD-
1 (40.1 kDa) is expressed in sporozoite stage while ALD-2 (39.8 kDa) is expressed
during the asexual blood cycle (Meier et al., 1992). X-ray analysis of ALD crystal
structure from P. falciparum revealed that ALD is a homotetrametric protein with
a molecular weight of 160kDa (Kim et al., 1998). Interestingly, the Plasmodium
ALD enzyme differs extensively from the mammalian orthologue, complicating the
classification of the enzyme into one of the three ALD classes (A, B and C).
3.1.2.5 Triosephosphate isomerase
The interconversion of DHAP and GAP, with enediol phosphate intermediate, is
catalysed by triosephosphate isomerase (TPI). The 28 kDa enzyme of P. falciparum
shows 42-45% homology to the eukaryotic isoenzymes, allowing for unique drug
development (Younis et al., 2014). Unlike the human TPI isomerase, the protein
crystal structure reveals that the serine to phenolalanine mutation on residue 96
causes the enzyme to exist in two distinct conformations, namely open and closed
catalytic loop, however, the influence the states have on the catalytic activity has
not been elucidated (Parthasarathy et al., 2002).
3.1.2.6 Glyceraldehyde 3-phosphate dehydrogenase
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, EC 1.2.1.12) catalyses the ox-
idation of GAP with NAD+ and inorganic phosphate to produce 1,3-bisphosphoglycerate
(B13PG) and NADH. The 36.7 kDa of P. falciparum protein has been expressed in
Escherichia coli and found to have 63.5% homology to the human eurythrocytic
counterpart (Srivastava et al., 1992). The heteromeric protein consists of four iden-
tical polypeptide chains that, using sulphydryl groups, catalyse the conversion with
a hemithioacetal intermediate (Daubenberger et al., 2000).
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3.1.2.7 Phosphoglycerate kinase
The conversion of B13PG and ADP to 3-phosphoglycerate (3PG) and ATP is catal-
ysed by 3-phosphoglycerate kinase (PGK, EC 2.7.2.3) with the help of Mg2+ and is
the first reaction in the glycolytic pathway to produce ATP. Inhibition by anti-serum
raised against the purified 45.5 kDa protein of P. falciparum does not influence the
eurythrocytic counterpart, which is supported by the gene analysis that showed that
only 60% similarity exists between the two enzymes (Grall et al., 1992). Two isoen-
zymes exist for the 3PG in P. falciparum, but the asexual blood-stage parasite only
produces a single 2.1 Kb mRNA transcript (Hicks et al., 1991). The crystaline struc-
ture analysis and the biochemical characterization of the enzyme has been studied
by Pal et al. (2004) and found that the enzyme is temperature sensitive and that
suramin inhibits the working of the enzyme.
3.1.2.8 Phosphoglycerate mutase
Phosphoglycerate mutase (PGM, EC 5.4.2.1) catalyses the interconversion of 3PG
to 2-phosphoglycerate (2PG). The crystal structure of one of the two putative isoen-
zymes of P. falciparum PGM was investigated by Hills et al. (2011), along with the
biochemical characterization of the the isoenzyme. In the study it was found that
PGM could dephosphorylate multiple metabolites, including F6P and F16BP, giv-
ing rise to the idea that PGM is a moonlighting enzyme with multiple functions
(Gomez-Arreaza et al., 2014).
3.1.2.9 Enolase
2PG to phosphoenol pyruvate (PEP) interconversion is catalyse by enolase (ENO,
EC 4.2.1.11). As with PGM, ENO (51.4 kDa) is also known to be a moonlighting en-
zyme with non-glycolytic function (Pal-Bhowmick et al., 2007b). The four isoforms
of ENO, also 2-phospho-D-glycerate hydrolase, are thought to be due to the phos-
phorylating post transcriptional modification, which could give rise to the different
functions of the enzyme. Pal-Bhowmick et al. (2004) biochemically characterised
the homodimer of P. yoelii and found that Na+ has a inhibitory effect, whilst K+
and cofactor Mg2+ have an activation effect. A 68% identity and 78% homology
exists between the Plasmodium and human orthologue ENO (Pal-Bhowmick et al.,
2007a).
3.1.2.10 Pyruvate kinase
The second ATP generating step in glycolysis is catalysed by the homotetramer,
pyruvate kinase (PK). The 55.6 kDa enzyme converts ADP and PEP to ATP and
pyruvate. Unlike most analogues of PK, the enzyme is not affected by F16BP or
G6P, but inhibited by ATP and citrate. Chan and Sim (2004) overexpressed in E.
coli and characterized PK and found that the affinity for ADP and PEP appears
to be greater than that of the mammalian isoenzymes. Interestingly, a genetic PK
deficiency confers resistance to malarial infection; The reason for the resistance is
due to invasion defect of the erythrocytes and the preferential macrophage clearance
(Ayi et al., 2008).
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3.1.2.11 Lactate Dehydrogenase
Lactate dehydrogenase (LDH, EC 1.1.1.27) catalyses the reduction of pyruvate and
NADH to lactate and NAD+. A single 1.6 kB gene encodes for the 33 kDa enzyme
that contains several distinct amino acid sequences to that of the eurythrocytic LDH.
Bzik et al. (1993) expressed LDH in Escherichia coli and characterised the purified
enzyme whilst (Vander Jagt et al., 1981) performed partial purification and char-
acterization from P. falciparum extract. LDH has been targeted as an inexpensive
field diagnostic target by measuring the LDH activity in the presence of cofactor
3-acetyl puridine, a reaction that is very slow with RBC LDH but shows increase
activity in parasite LDH (Makler and Hinrichs, 1993). Parasitemia calculation us-
ing 3-acetyl puridine and measuring LDH activity is comparible to using microscopy
and 3H-hypoxanthine (Makler et al., 1993)(Chulay et al., 1983).
3.2 Methods and Materials
3.2.1 Materials
For increased accuracy and consistency, all the substrates, metabolites and enzymes
used in the experiments were purchased from Sigma-Aldrich unless otherwise stated
in text. The buffers used throughout this study, specifically the enzyme assay buffer
(EAB), are described in Appendix A. The creators of the equipment used in this
study is given in text.
3.2.2 Isolation of intact Parasites
The rats are euthanized followed by blood collection after reaching 12 days of infec-
tion or reaching critically low health. Critically low health criteria included paral-
ysis, a comatose state, weight loss exceeding 15% of total starting weight, seizures,
severe weakness, difficulty breathing and ataxia. Comas and paralysis are clear
indicators of cerebral malaria, which is uncommon in Winstar rats, but not im-
probable (Kamiyama et al., 1987). None of the rats used in this study suffered
from cerebral malaria. Maximal sterile blood collection was made possible by us-
ing a method similar to cardiac puncture. The rats are anaesthetised with either
4% isoflurane and kept anaesthetized with 1.5% isoflurane or 100 mg/kg ketamine-
xylazine. Ketamine-xylazine sedation proved difficult as the xylazine slows the heart
rhythm and resulted in premature cardiac arrest (Hsu et al., 1985). Blood sample
colletion was done through a method similar to cardiac puncture, but the blood was
drawn from the caudal vena cava (Parasuraman et al., 2010). Immediately after the
blood collection, the collected blood is injected into a sterile tube with CPDA fluid
(1 part CPDA to 7 parts whole blood) to stop the blood from coagulating. The
collected blood could be used for either isolation of intact parasites or culturing in
culture flasks.
Various Plasmodium spp. trophozoite isolation methods exist, including filter
agglutination and lysis, glycerol-enhanced osmotic shock, saponin treatment and
RBC-antibody lysis (Wongsrichanalai et al., 2002). The saponin isolation method
used for isolating the intact parasites is based on the trophozoits techniques ac-
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cording to Saliba and Kirk (1999) and, due to the semi-asynchronous growth of P.
berghei, some of the parasites might have been lost during the process. Saponin
lysis as a means of parasite isolation was used because of the ease and success of
the protocol. Sapogenin, the active compound in saponin, irreversibly permeates
the lipid bilayer of RBCs (Baumann et al., 2000). As a wash step, whole blood with
CPDA solution, collected from euthanized rats, was diluted with culture medium
(CM) and centrifuged (750 × g, 7 min) and supernatant removed. Washed whole
blood was resuspended in CM and 5% saponin was added to a final concentration of
0.05% saponin. After the addition of saponin, the mixture is inverted for less than
30 seconds until the colour of the suspended blood turns from red to black where-
after it is immediately centrifuged at 1700 × g for 7 minutes and the supernatant
pipetted out. The aliquot was resuspended in CM and centrifuged (1300 × g, 7 min)
as a wash step. Glucose-free wash buffer was used to resuspend the aliquots of the
solutions, after the CM containing supernatant was pipetted out and centrifuged
(6500 RPM, 5 minutes, MSE Micro centaur centrifuge). The isolated parasites were
then either stored at -80°C for later lysis or immediately lysed using three freeze-
thaw cycles (liquid nitrogen) with intermittent sonification (30 seconds). The lysed
parasites were then centrifuged (13 000 × g) and the supernatant, containing the
glycolytic enzymes, stored at -80°C to be used for the kinetic studies.
3.2.3 Protein concentration determination
The protein concentration of each lysate was measured using Bradford’s reagent
(Bradford, 1976). In a 96 well plate, 10 µl of series of parasite lysate extract dilutions
or bovine serum albumin (0 - 1 mg/ml) was added to 190 µl of filtered Bradford’s
reagent. The plate was incubated away from direct light for 15 minutes before the
absorbance (595 nm) was measured using a spectrophotomer (BioTek PowerWave
340).
3.2.4 Characterizing glycolytic enzymes
The isolated glycolytic enzymes were measured in terms of their maximal veloci-
ties at a specific substrate concentration. To measure the velocities, the rates of
oxidation and reduction of secondary metabolites, NAD(P)+ and NAD(P)H, were
measured by observing the change in absorbance (340 nm) using a spectrophotome-
ter (BioTek PowerWave 340). All enzymes that did not directly reduce or oxidise the
secondary metabolites, were linked to reactions that do by adding linking enzymes
(final concentration of 5 U/ml).
3.2.4.1 Hexokinase
The forward reaction velocity of HK was measured by linking the production of
G6P to the reduction of NADP+ (0.8 mM) through G6PDH as linking enzyme.
Characterization of the enzyme was done by varying the substrate, Glu (0 - 10
mM) and ATP (0 - 4mM) concentrations and varying the product, ADP (0 - 10
mM), concentration. During each experiment, a constant concentration for each of
the metabolites not varied, Glu (10 mM), ATP (2 mM), G6P (0 mM) and ADP
(0 mM), was used. Inhibition by G6P (0 - 10 mM) was measuring by linking the
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production of ADP to the oxidation of NADH through PK and LDH with PEP (2
mM).
3.2.4.2 Glucosephosphate isomerase
Both the forward and the reverse reaction velocities of GPI were measured. Pro-
duction of F6P was characterized by varying the substrate, G6P (0 - 10 mM), and
measuring the oxidation rate of NADH (0.8 mM) by α-glycerol phosphate dehy-
drogenase (α-GlyPDH) with ALD, TPI and PFK as linking enzymes. The reverse
reaction was characterized by varying product of GPI, F6P (0 - 2 mM), and measure
the reduction NADP+ (0.8 mM) by G6PDH.
3.2.4.3 Phosphofructokinase
The velocities for the forward and inhibition of the forward reaction were measured
as the reaction is irreversible. For all experiments, except for the measurement of
the influence of ATP, the ATP was kept constant at a concentration of 1.25 mM.
Specific activity of the forward reaction was measured by varying F6P (0 - 10 mM)
and varying the ATP (0 - 4 mM) while using a F6P concentration of 0.5 mM and
1 mM. The inhibition of PFK was measured by varying the F16BP (0 - 10 mM)
concentration whilst keeping F6P constant at 10 mM. Furthermore, the extent of
inhibition of ADP (0 - 2 mM) was measured by using a F6P concentration of 0.5
mM and 1mM. The reaction for the variation for F16BP and ADP included NADH
(0.8 mM), LDH, PK and PEP (2 mM) as linking metabolites and enzymes while the
reactions that relied on the variation of F6P and ATP included NADH (0.8 mM),
αGlyPDH, ALD and TPI as the linking enzymes and metabolites.
3.2.4.4 Aldolase
Specific activity for ALD was only measured in the forward reaction because no
reverse linking reaction has been identified as PFK is irreversible. The reaction
rates were measured by varying the concentration of F16BP (0 - 1 mM). The link-
ing enzymes included αGlyPDH and TPI. NADH (0.8 mM) served as the linking
metabolite.
3.2.4.5 Triosephosphate isomerase
The forward reaction of GAPDH could not be achieved, consequently, only the
specific activity for the reverse direction of TPI could be measured by varying the
GAP (0 - 0.8 mM) concentration. αGlyPDH served as the linking enzyme along
with NADH (0.8 mM).
3.2.4.6 Glyceraldehyde 3-phosphate dehydrogenase
Only the reverse reaction of GAPDH could be measured due to either error in exper-
imental design or reasons unknown to this researcher. Since B13PG is chemically
unstable, the velocity was measured by varying 3PG (0 - 2.5 mM) concentration
whilst keeping the NADH (0.8 mM) concentration constant and varying NADH (0 -
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0.4 mM) concentration whilst keeping the 3PG concentration constant at 5 mM. For
both the reactions, PGK is added to convert 3PG to B13PG (complete conversion
is assumed).
3.2.4.7 Phosphoglycerate kinase
The specific activity of PGK’s reverse reaction is measured by varying the two
substrates, 3PG (0 - 2.5 mM) and ATP (0 - 5 mM), concentrations linked to the
oxidation of NADH (0.8 mM) through GAPDH as a linking enzyme. The extent of
inhibition of ADP (0 - 4 mM) was also measured by varying the ADP concentration.
For all the experiments, the reverse metabolites, 3PG (10 mM) and ATP (5 mM),
were kept constant unless being the subject of the experiment. The forward reaction
could not be measured enzymatically since one of the linking enzymes, PK, also uses
ADP as a substrate.
3.2.4.8 Phosphoglycerate mutase
The forward velocity of PGM was measured by varying the substrate, 3PG (0 - 10
mM), concentration and linking the creation of 2PG to the oxidation of NADH (0.8
mM) via LDH along with PK and ENO as linking enzymes and ADP (2 mM) as
linking enzyme. For both PGM and ENO, the reverse reaction could not be mea-
sured, even at saturation concentrations to be used as a positive control. The reason
for the inability to measure the reverse reactions is unknown to this researcher.
3.2.4.9 Enolase
The forward velocity of ENO was measured by varying the substrate, 2PG (0 - 5
mM), concentration and linking the creation of PEP to the oxidation of NADH
(0.8 mM) via LDH along with PK as linking enzyme and ADP (2 mM) as linking
enzyme.
3.2.4.10 Pyruvate kinase
Specific activity of PK was only measured in the forward reaction, due to the ir-
reversible nature of PK, by varying the concentration of the substrates, ADP (0 -
2.5 mM) and PEP (0 - 4 mM), and linking the creation of Pyr to the oxidation of
NADH (0.8 mM) via LDH. The extent of PK’s forward inhibition was measured by
varying the concentration of the inhibitors, ATP (0 - 4 mM) and Pyr (0 - 100 mM).
For the forward reactions, ADP measurements by using a PEP concentration of 5
mM and PEP measurements were done by using a ADP concentration of 0.5 mM
and 2.5 mM. Inhibition by ATP was measured by using an ADP concentration of
0.5 mM and PEP concentration of 1.25 mM and 2.5 mM. Pyruvate inhibition was
measured by using a ADP concentration of 1 mM and PEP concentration of 1.25
mM with LDH as linking enzyme.
3.2.4.11 Lactate Dehydrogenase
LDH was characterised in both directions. The forward reaction velocity was mea-
sured by varying the substrate, Pyr (0 - 2 mM) and NADH (0 - 0.4 mM), concen-
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trations. The accompanying substrate was kept constant, which included Pyr (2.5
mM) during the NADH testing and NADH (0.8 mM) during the Pyr testing. The
velocities of the reverse direction were measured by varying the products, Lac (0 -
10 mM) and NAD+ (0 - 1 mM), while keeping the accompanying product, Lac (20
mM) and NAD+ (2 mM), constant. No linking enzymes or metabolites were used
during LDH characterization.
3.2.5 Computational Analysis and Statistics
Data obtained from the spectrophotomer was interpreted with GraphPad Prism
5.0 to obtain the maximal activity of each reaction which was normalised with the
extract protein concentration to produce the specific activity. The specific activity
of each reaction was in turn imported into Mathematica version 10.0 to produce
graphs and fitted lines, as well as the kinetic parameters and SEM.
3.3 Results and Discussion
Very promising results were obtained for the kinetic study, showing many similari-
ties to the work done on P. falciparum. Every data point was measured in technical
triplicates and the standard error of means (SEM) for technical replicates of the
different data points is omitted as the SEM was negligibly small (fall within the
symbol size) in the vast majority of the data points. Four data points were obtained
per experiment, but the limited available biomass obtained from the successful isola-
tion, forced prioritizing of certain enzyme characterizations. Here follows the results
obtained from the enzyme assays and the subsequent rate equations fittings.
3.3.1 Hexokinase
The first reaction characterised is that of HK. HK, the first enzyme of glycolysis
and catalyses the first reaction reaction in the glycolytic model (figure 3.1), con-
verting glucose and Mg-ATP-complex to G6P, Mg-ADP-complex and H+. With the
assumption that the reaction is irreversible due to the large Keq from literature, the
enzyme was characterised for the forward reaction in terms of glucose and ATP as
its substrates and ADP and G6P as the enzymes inhibitory products. Figure 3.2
shows the data obtained from the kinetic study with the velocity of the reaction
plotted against the concentration of the substrate or product. The glucose satura-
tion curve is not clear from the data points obtained, but the product inhibition
from ADP and G6P follow normal Michaelis-Menten curves. ATP appears to in-
hibit the reaction above a certain concentration, similar to results obtained from
Kumar and Banyal (1996), suggesting that hexokinase is sensitive to substrate inhi-
bition by ATP; consequently, substrate inhibition was then added to the equation.
A Michaelis-Menten equation (eq 3.5) with substrate inhibition and replacement of
the Vmax for the reverse, by using the Haldane relation, reaction was then plotted to
the data points, represented by the curves in 3.2. The curves appear to adequately
fit the data and the Michaelis-Menten constants along with the Vmax forward and
Keq, from literature, is displayed in table 3.1. The kinetic parameters show good
agreement to the work of Penkler et al. (2015) on P. falciparum, shown in table 3.1.
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Figure 3.2: Results from the kinetic characterization and subsequent equation fitting of P.
berghei hexokinase. The velocities of the forward reaction of HK in terms of the substrates,
(A) Glu and (B) ATP, are shown with the inhibition of the products, (C) ADP and (D)
G6P. Equation 3.5 is fitted to the data set to produce the fitted lines that describe the data
well (adjusted R2 = 0.98).
3.3.2 Glucosephosphate isomerase
The reversible conversion of G6P to F6P is mediated by GPI and is the second step
in glycolysis. The kinetic parameters of the enzyme were characterised by varying
the substrate concentration and measuring the velocity of F6P production and by
varying the product concentration and measuring the velocity of G6P creation. Data
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Table 3.1: Enzyme kinetic parameters for P. berghei HK. The Michaelis constants for the
different metabolites and the maximal velocity of the forward reaction that were fitted using
the data in figure 3.2 and equation 3.5 are displayed in the table alongside the values Penkler
et al. (2015) fitted or used for P. falciparum. The asymptotic standard error is given with
all the fitted values.
Parameter Fitted Value Literature value
Vf (µmol·min−1·mg−1) 0.47 ± 0.02 0.39 ± 0.09
Kglu (mM) 0.33 ± 0.15 0.17 ± 0.02
Katp (mM) 1.50 ± 0.22 0.7 ± 0.03
Kg6p (mM) 0.06 ± 0.03 0.04 ± 0.01
Kadp (mM) 0.33 ± 0.15 0.8 ± 0.1
Keq (mM) - 1310
obtained from the kinetic study is displayed on figure 3.3 A and B. Substrate inhibi-
tion was observed at higher concentration, above 2.5 mM, of G6P. Using a random
order uni-uni Michaelis-Menten equation (eq 3.6) with substrate inhibition factor,
the fitted curves on figure 3.3 A and B was obtained. Table 3.2 presents the values
for the maximal velocities, both forward and reverse, the Michaelis-Menten con-
stants for the reaction and the Keq that was calculated using the Haldane relation.
All the kinetic parameters fitted well (p < 0.01), except for Kf6p. No literature
on substrate inhibition of G6P could be found to date. The substrate inhibition
could be due to inhibition by 6-phosphogluconate (Parr, 1956). According to Carter
(1970), P. berghei produces 6-phosphogluconate dehydrogenase as a means to create
NADPH for combating oxidative stress via the pentose phosphate pathway. Since
no NADPH is added to the assay the reaction is unlikely. Further investigation is
needed to elucidate the cause of the substrate inhibition.
vGPI =
g6p·Vf
Kg6p − f6p·VrKf6p(
g6p
Kg6p + 1
) (
f6p
Kf6p +
g6p
Kg6p + 1
) (3.6)
Table 3.2: Enzyme kinetic parameters for P. berghei GPI. The Michaelis constants for
the different metabolites and the maximal velocities of the forward reaction and reverse
direction that were fitted using the data in figure 3.3 and equation 3.6 are displayed in
the table alongside the values Penkler et al. (2015) fitted or used for P. falciparum. The
asymptotic standard error is given with all the fitted values.
Parameter Fitted Value Literature value
Vf (µmol·min−1·mg−1) 1.77 ± 0.16 3.7 ± 0.02
Vr (µmol·min−1·mg−1) 0.29 ± 0.07 1.4 ± 0.03
Kg6p (mM) 2.06 ± 0.53 1.0 ± 0.1
Kf6p (mM) 0.19 ± 0.17 0.10 ± 0.01
Keq (mM) 0.55 0.3 ± 0.1
Stellenbosch University  https://scholar.sun.ac.za
42 CHAPTER 3. ENZYMES KINETICS
A
0 5 10 15 20
0.0
0.1
0.2
0.3
0.4
0.5
G6P (mM)
vP
G
I(U/m
g)
B
0.0 0.5 1.0 1.5 2.0
-0.30
-0.25
-0.20
-0.15
-0.10
-0.05
0.00
F6P (mM)
vP
G
I(U/m
g)
Figure 3.3: Results from the kinetic characterization and subsequent equation fitting of
P. berghei phoshoglucose isomerase. The velocities of the forward (A) and reverse (B)
reactions of the enzymes are displayed by altering the concentration of the substrate, G6P,
and product, F6P, respectively. Equation 3.6 is fitted to the data set to produce the fitted
lines that describe the data well (adjusted R2 = 0.94).
3.3.3 Phosphofructokinase
Phosphofructokinase is a key-regulatory enzyme in the glycolytic pathway and catal-
yses the conversion of F6P and ATP to F16BP and ADP. Figure 3.4 shows the results
of the kinetic experiments performed on PFK. The problems with reproducibility
of the experiment, availability of P. berghei extract and human error allowed for
only one experiment to be performed for two different concentrations of F6P. Since
PFK shows substrate inhibition for ATP and product inhibition, two different con-
centrations of F6P was used for the characterization of the binding of the primary
metabolites. Equation 3.7 was used to plot the fitted lines on figure 3.4. The fitted
lines describe the data adequately, but more data points are needed to produce a
better fit. The combined work of Buckwitz et Al (1990a, 1990b and 1988) used
Hill’s coefficient to describe the effect the homo-oligomer nature of PFK had on the
activation and inhibition of the various metabolites reacting with PFK. Future work
on the model necessitates investigation into the possible of use of Hill’s coefficient to
describe the data. Michaelis-Menten constants and the maximal forward velocity of
the reaction is displayed in Table 3.3 alongside the values Penkler (2009) obtained
in his M.Sc thesis. The characterization of PFK needs to be repeated and Hill’s
coefficient applied to the equations to present a more adequate representation of the
kinetic parameters of PFK.
vPFK = atp · f6p ·Vf
Katp ·Kf6p
(
atp
Katp + 1
) (
adp
Kadp +
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) (
f16bp
Kf16bp +
f6p
Kf6p + 1
) (3.7)
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Table 3.3: Enzyme kinetic parameters for P. berghei PFK. The Michaelis constants for
the different metabolites and the maximal velocity of the forward reaction that were fitted
using the data in figure 3.4 and equation 3.7 are displayed in the table alongside the values
Penkler et al. (2015) fitted or used for P. falciparum. The asymptotic standard error is given
with all the fitted values.
Parameter Fitted Value Literature value
Vf (µmol·min−1·mg−1) 2.1 ± 2.8 1.9 ± 0.3
Katp (mM) 3.6 ± 0.86 0.79 ± 0.04
Kf6p (mM) 0.21 ± 0.40 1.07 ± 0.06
Kf16bp (mM) 3.2 ± 0.88 3.6 ± 0.5
Kadp (mM) 0.09 ± 0.16 0.7 ± 0.1
3.3.4 Aldolase
Aldolase catalyses the aldol cleaving of F16BP into two triose phosphates, namely
DHAP and GAP. The forward reaction of the enzyme was characterized by varying
the concentration of the substrate, F16BP. Results for the kinetic study is displayed
in figure 3.5. Using a random order uni-bi Michaelis-Menten equation (eq 3.8), a line
was fitted to the equation which fits the data well. The near irreversible nature of
PFK (if used as linking enzyme) did not allow for the reverse characterization of the
enzyme and the Haldane relationship with the Keq from Penkler et al. (2015), was
used. Due to the presence of TPI, the binding coefficients could not be measured
for either GAP or DHAP and so KGAP and KDHAP was used from the work of
Penkler et al. (2015)l. A summary of the kinetic data obtained is displayed in table
3.4, alongside Penkler’s results. A 20 times difference is observed between the two
different Vf ’s. The low Vf could be due to the low pH of 7.17 (optimal pH of
between pH 7.8 and 8.2) or due to degradation over time since it has been observed
that 31% of aldolase is destroyed in 24 hours at 4◦ C (Kumar and Banyal, 1997).
The Kf16bp obtained closely matches that of Kumar and Banyal (1997) (0.025), but
is more than 2-fold lower than the value determined by Penkler et al. (2015).
vALD =
f16bp ·Vf ·
(
1− dhap·gapf16bp·Keq
)
Kf16bp
(
dhap·gap
Kdhap·Kgap +
dhap
Kdhap +
f16bp
Kf16bp +
gap
Kgap + 1
) (3.8)
3.3.5 Triosephosphate isomerase
The reversible conversion from DHAP to GAP is catalysed by TPI. The reaction
was only characterised in the reverse direction (figure 3.6), as the forward reaction of
the linking enzyme, GAPDH, would not react. A uni-uni Michaelis-Menten equation
(eq 3.9) with PEP inhibition and Haldane relation to replace the maximal forward
velocity was used to plot the line on the graph and calculate the kinetic parameters
in table 3.5. The Kdhap, Kipep and Keq was used from Penkler et al. (2015) as this
could not be measured. The reaction occurred without the addition of GAP, which
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Figure 3.4: Results from the kinetic characterization and subsequent equation fitting of
P. berghei phosphofructokinase. The velocities of the forward reaction of PFK in terms of
the substrates, (A) F6P and (C) ATP, is shown with the inhibition by the products, (B)
F16BP and (D) ADP. Equation 3.7 is fitted to the data set to produce the fitted lines that
adequately describe (adjusted R2 = 0.97).
negatively influences the accuracy of the parameter fitting.
vTPI =
dhap·Keq·Vr
Kgap − gapVrKgap
dhap
Kdhap +
gap
Kgap
(3.9)
3.3.6 Glyceraldehyde 3-phosphate dehydrogenase
The sixth step in the central carbon metabolism is the convertion of GAP, NAD+ and
inorganic phosphate to B13PG and NADH which is catalysed by glyceraldehyde-
3-phosphate dehydrogenase. GAPDH was only characterised (figure 3.7) in the
reverse direction for both enzyme products, (A) B13PG and (B) NADH, as the
forward reaction could not be measured. Time constraints did not allow further
investigation as to the exact reason why the forward reaction could not be measured.
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Table 3.4: Enzyme kinetic parameters for P. berghei ALD. The Michaelis constants for
the different metabolites and the maximal velocity of the forward reaction that were fitted
using the data in figure 3.5 and equation 3.8 are displayed in the table alongside the values
Penkler et al. (2015) fitted or used for P. falciparum. The asymptotic standard error is given
with all the fitted values.
Parameter Fitted Value Literature value
Vf (µmol·min−1·mg−1) 0.013 ± 0.0008 0.27 ± 0.01
Kf16bp (mM) 0.029 ± 0.013 0.068 ± 0.004
Kgap (mM) - 0.05 ± 0.02
Kdhap (mM) - 0.11 ± 0.09
Keq (mM) - 0.09
0.0 0.2 0.4 0.6 0.8 1.0
0.000
0.002
0.004
0.006
0.008
0.010
0.012
F16P (mM)
vA
LD
(U/m
g)
Figure 3.5: Results from the kinetic characterization and subsequent equation fitting of
P. berghei aldolase. The velocities of the forward reaction of ALD, measured by varying the
substrate, F16BP, concentration is shown. Equation 3.8 is fitted to the data set to produce
the fitted lines that describe the data well (adjusted R2 = 0.99).
The velocities of the reverse reaction was measured by altering PG3 concentration
with the addition of ATP and PGK which was assumed to be readily converted back
into B13PG due to PGK’s high Keq. Using a random order bi-bi Michaelis-Menten
equation (eq 3.10) in combination with the Haldane relation, lines were fitted to the
data set that described the data well. Kinetic parameters for the characterization
are displayed in table 3.6. The maximal velocity of the reverse reaction is 10 times
lower than the velocity obtained by Penkler et al. (2015) for P. falciparum and the
binding coefficient for B13PG is 20 times greater, necessitating investigation into
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Table 3.5: Enzyme kinetic parameters for P. berghei TPI. The Michaelis constants for the
different metabolites and the maximal velocity of the reverse reaction that were fitted using
the data in figure 3.6 and equation 3.9 are displayed in the table alongside the values Penkler
et al. (2015) fitted or used for P. falciparum. The asymptotic standard error is given with
all the fitted values.
Parameter Fitted Value Literature value
Vr (µmol·min−1·mg−1) 5.1 ± 3.6 15 ± 1
Kgap (mM) 0.50 ± 0.72 0.34 ± 0.04
Kdhap (mM) - 2.0 ± 0.3
Kipep (mM) - 0.016 ± 0.002
Keq (mM) - 0.08 ± 0.03
0.0 0.2 0.4 0.6 0.8
0.0
0.5
1.0
1.5
2.0
2.5
3.0
GAP (mM)
vT
P
I(U/m
g)
Figure 3.6: Results from the kinetic characterization and subsequent equation fitting of P.
berghei triosephosphate isomerase. The velocities of the reverse reaction of TPI, measured
by varying the enzyme product, GAP, concentration are shown. Equation 3.9 is fitted to
the data set to produce the fitted lines that does not describe the data well (adjusted R2 =
0.90).
the reason for the large difference.
vGAPDH =
gap·Keq·nad·Vr
Kb13pg·Knadh − b13pg·nadh·VrKb13pg·Knadh(
b13pg
Kb13pg +
gap
Kgap + 1
) (
nad
Knad +
nadh
Knadh + 1
) (3.10)
3.3.7 Phosphoglycerate kinase
The conversion of B13PG and ADP to PG3 and ATP is catalysed by the enzyme
phosphoglycerate kinase and functions as the first ATP producing step. Charac-
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Table 3.6: Enzyme kinetic parameters for P. berghei GAPDH. The Michaelis constants for
the different metabolites and the maximal velocity of the reverse reaction that were fitted
using the data in figure 3.7 and equation 3.10 are displayed in the table alongside the values
Penkler et al. (2015) fitted or used for P. falciparum. The asymptotic standard error is given
with all the fitted values.
Parameter Fitted Value Literature value
Vr (µmol·min−1·mg−1) 0.14 ± 0.009 1.2 ± 0.3
Kgap (mM) - 0.9 ± 0.1
Kb13pg (mM) 0.55 ± 0.11 0.024 ± 0.002
Knad (mM) - 0.57 ± 0.06
Knadh (mM) 0.011 ± 0.005 0.029 ± 0.004
Keq (mM) - 0.0035
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Figure 3.7: Results from the kinetic characterization and subsequent equation fitting of P.
berghei glyceraldehyde 3-phosphate dehydrogenase. The velocities of the reverse reactions
of GAPDH, measured by varying the enzyme products, (A) B13PG and (B) NADH, con-
centrations is shown. Equation 3.10 is fitted to the data set to produce the fitted lines that
describes the data well (adjusted R2 = 0.99).
terization of PGK was only possible in the reverse direction by measuring GAPDH
activity, because the ADP is a substrate of one of the possible forward linking en-
zymes, PK, and B13PG is unstable. Figure 3.8 shows the results of the kinetic study
done on PGK for both the enzyme’s products, ATP and PG3, as well as inhibition
by the substrate ADP. A random order bi-bi Michaelis-Menten equation (eq 3.11),
along with the Haldane relation to compensate for the inability to measure the for-
ward reaction, was fitted to the data set to produce the fitted lines that describe
the data well. The Michaelis constants and maximal velocities of the fitted lines are
presented in table 3.7. Due to inability to achieve a forward reaction for GAPDH,
KB13PG for PGK could not be measured and instead was used from the work of
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Penkler et al. (2015).
vPGK =
atp · pg3 ·Vr
(
adp·b13pg·Keq
atp·pg3 − 1
)
Katp ·Kpg3
(
adp
Kadp +
atp
Katp + 1
) (
b13pg
Kb13pg +
pg3
Kpg3 + 1
) (3.11)
Table 3.7: Enzyme kinetic parameters for P. berghei PGK. The Michaelis constants for
the different metabolites and the maximal velocity of the reverse reaction that were fitted
using the data in figure 3.8 and equation 3.11 are displayed in the table alongside the values
Penkler et al. (2015) fitted or used for P. falciparum. The asymptotic standard error is given
with all the fitted values.
Parameter Fitted Value Literature value
Vr (µmol·min−1·mg−1) 0.64 ± 0.03 0.39 ± 0.09
Kadp (mM) 0.33 ± 0.15 0.15 ± 0.01
Katp (mM) 1.02 ± 0.17 0.77 ± 0.05
K3pg (mM) 1.42 ± 0.14 0.27 ± 0.02
Kb13pg (mM) - 0.013
Keq (mM) - 3200
3.3.8 Phosphoglycerate mutase
The reversible interconversion of PG3 to PG2 is catalysed by phosphoglycerate mu-
tase. Only the forward reaction could be characterized for PGM. Exact reason for
the inability to measure the forward reaction could not be determined during the
experimental phase of the project and requires further investigation. The data ob-
tained from the kinetic study is displayed on figure 3.9 and the lines describe the
data very well. The fitted lines on the figure were produced by applying a uni-uni
Michaelis-Menten equation along with the Haldane relations to compensate for the
reverse reaction to the data set. Kinetic parameters for the fitted equation (eq 3.12)
are presented in table 3.8. Since the reverse reaction could not be measured, the
Kpg2 and Keq was used from the work of Penkler et al. (2015).
vPGM =
pg3·Vf
Kpg3 − pg2·VfKeq·Kpg3
pg2
Kpg2 +
pg3
Kpg3 + 1
(3.12)
3.3.9 Enolase
The metalloenzyme, enolase, is responsible for catalysing the interconversion of PG2
and PEP. Similar to PGM, only the forward reaction could be kinetically measured
and the results of the kinetic experiments for ENO are presented in figure 3.10. Using
a uni-uni Michaelis-Menten equation, along with the Haldane relation to replace the
maximal velocity of the reverse reaction, and applying it (eq 3.13) to the data set,
the fitted lines were produced which describe the data well. the kinetic parameters
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Figure 3.8: Results from the kinetic characterization and subsequent equation fitting of P.
berghei phosphoglycerate kinase. The velocities of the reverse reactions of PGK, measured
by varying the enzyme products, (A) ATP and (B) PG3, concentrations with inhibition
of the enzyme substrate, (C) ADP, are shown. Equation 3.11 is fitted to the data set to
produce the fitted lines that describes the data well (adjusted R2 = 1.00).
for the fitted lines are displayed in table 3.9. The lack of characterization of the
reverse reaction led to the use of the Kpep and Keq from Penkler et al. (2015). It
should also be noted that the excessive Mg2+ concentration, which is known to
inhibit the reaction, could have caused at least 20% inhibition at concentration of
10 mM and that the kinetic measurements were done at a pH lower than that of the
ideal pH (7.4 to 7.6), but rather at a physiological pH of 7.17 (Pal-Bhowmick et al.,
2004).
vENO =
pg2·Vf
Kpg2 − pep·VfKeq·Kpg2
pep
Kpep +
pg2
Kpg2 + 1
(3.13)
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Table 3.8: Enzyme kinetic parameters for P. berghei PGM. The Michaelis constants for
the different metabolites and the maximal velocity of the forward reaction that were fitted
using the data in figure 3.9 and equation 3.12 are displayed in the table alongside the values
Penkler et al. (2015) fitted or used for P. falciparum. The asymptotic standard error is given
with all the fitted values.
Parameter Fitted Value Literature value
Vf (µmol·min−1·mg−1) 0.25 ± 0.01 0.87 ± 0.09
Kpg2 (mM) - 0.32 ± 0.02
Kpg3 (mM) 3.0 ± 0.44 1.7 ± 0.1
Keq (mM) - 0.30
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Figure 3.9: Results from the kinetic characterization and subsequent equation fitting of
P. berghei PGM. The velocities of the forward reaction of PGM, measured by varying the
enzyme substrate, PG3, concentration are shown. Equation 3.12 is fitted to the data set to
produce the fitted lines that describe the data well (adjusted R2 = 1.00).
3.3.10 Pyruvate kinase
The second ATP yielding reaction is the conversion of PEP and ADP to Pyr and
ATP, catalysed by the enzyme pyruvate kinase with a magnesium ion as cofactor.
The reaction is assumed to be irreversible due to the large difference in free energy
(Emmerling et al., 2002). PK was characterised in the forward direction (figure 3.11)
by varying the two substrates, PEP and ADP, and the inhibition by the products,
ATP and Pyr, was also measured with a LDH linked assay. Since PK is a morpheein
protein and subject to allosteric regulation, the MWC equation was used with an
irreversible bi-substrate Michaelis-Menten equation (eqns 3.14 and 3.15) to plot
the fitted lines on the graphs. The fitted lines do not adequately describe the
data obtained from the kinetic experiments. Additional data points are needed for
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Table 3.9: Enzyme kinetic parameters for P. berghei ENO. The Michaelis constants for
the different metabolites and the maximal velocity of the forward reaction that were fitted
using the data in figure 3.10 and equation 3.13 are displayed in the table alongside the values
Penkler et al. (2015) fitted or used for P. falciparum. The asymptotic standard error is given
with all the fitted values.
Parameter Fitted Value Literature value
Vf (µmol·min−1·mg−1) 0.56 ± 0.06 1.3 ± 0.4
Kpg2 (mM) 0.62 ± 0.30 0.52 ± 0.04
Kpep (mM) - 1.3 ± 0.1
Keq (mM) - 5.7
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Figure 3.10: Results from the kinetic characterization and subsequent equation fitting of
P. berghei enolase. The velocities of the forward reaction of ENO, measured by varying the
enzyme substrate, PG2, concentration are shown. Equation 3.13 is fitted to the data set to
produce the fitted lines that describe the data well (adjusted R2 = 0.99).
greater accuracy. A summary of the kinetic parameters, which includes the Michaelis
constants, Vmax for the forward reaction and the MWC parameters is given in table
3.10. The substrate binding sites, labeled “n” in the equations and fitted values
represents the number of allosteric binding cites and was used from the work of
Penkler et al. (2015). Significant difference exist between the fitted values for P.
berghei and P. falciparum, from the work of Penkler et al. (2015), which is evident
when looking at goodness of fit of the curves to the data points, necessitating repeats
for better results.
vPK = adp · pep ·Vf
Kadp ·Kpep(L+ 1)
(
adp
Kadp + 1
) (
pep
Kpep + 1
) (3.14)
Stellenbosch University  https://scholar.sun.ac.za
52 CHAPTER 3. ENZYMES KINETICS
L = L0
(( adp
Kiadp +
atp
Kiatp
)n
+ 1
)(( pep
Kipep +
pyr
Kipyr
)n
+ 1
)
(3.15)
Table 3.10: Enzyme kinetic parameters for P. berghei PK. The Michaelis constants for the
different metabolites, the maximal velocity of the forward reaction and the Monod-Wyman-
Changeux elements that were fitted using the data in figure 3.11 and equations 3.14 and
3.15 are displayed in the table alongside the values Penkler et al. (2015) fitted or used for
P. falciparum. The asymptotic standard error is given with all the fitted values.
Parameter Fitted Value Literature value
Vf (µmol·min−1·mg−1) 0.36 ± 0.59 2.3
Kadp (mM) 0.92 ± 0.82 0.30 ± 0.050
Kpep (mM) 0.36 ± 0.53 0.39 ± 0.047
Kipyr (mM) 3.19 ± 0.56 69 ± 6.7
Kiatp (mM) 3.30 ± 0.54 1.4 ± 0.12
Kiadp (mM) 2.9 ± 1.0 1.9 ± 0.15
Kipep (mM) 3.30 ± 0.56 2.8 ± 0.24
L0 (mM) 0.12 ± 0.12 0.20 ± 0.09
n (mM) 4 4
3.3.11 Lactate dehydrogenase
The most complete kinetic characterization was that of the kinetic analysis of the
enzyme lactate dehydrogenase which catalyses the conversion of Pyr and NADH to
Lac and NAD+. Both the velocities of the forward and reverse reaction of the enzyme
was measured by varying the concentrations of the substrates and the products
whilst keeping the other metabolites constant; data displayed in figure 3.12. The
fitted lines were constructed by applying a random order bi-bi Michaelis-Menten
equation (eq. 3.16) to the data set which describes the data well. Table 3.11 was
constructed from the kinetic parameters of the equation fitting. The majority of the
kinetic parameters correlate to the values obtained for P. falciparum, from the work
of Penkler et al. (2015), well, except for the binding coefficient for lac and the Keq,
which differ by a few magnitudes.
vLDH =
nadh·pyr·Vf
Knadh·Kpyr − lac·nad·VrKlac·Knad(
lac
Klac +
pyr
Kpyr + 1
) (
nad
Knad +
nadh
Knadh + 1
) (3.16)
3.3.12 Summary
In this chapter we have partially characterized the kinetic parameters of P. berghei
glycolytic enzymes. The kinetic parameters obtained from the characterization are
summarised in table 3.12. The aim of this chapter was to assess the feasibility of
characterizing the different glycolytic enzymes and we have proven that this is indeed
possible. Some of the enzymes have incomplete characterizations and the parameters
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Figure 3.11: Results from the kinetic characterization and subsequent equation fitting of
P. berghei pyruvate kinase. The velocities of the forward reaction of PK, in terms of the
substrates, (A) ADP and (B) PEP, are shown with the inhibition of the products, (C) ATP
and (D) Pyr. Equations 3.14 and 3.15 is fitted to the data set to produce the fitted lines
that does not describe the data set well (adjusted R2 = 0.86).
that could not be measured was used from the work of Penkler et al. (2015). The
reasons for the incomplete characterizations will need to be investigated further to
complete a full kinetic parameter study. For further refining of parameters, the
kinetic assays will need to be repeated to collect more data points and the linking
enzymes varied to confirm that they do not hinder the maximal velocities of the
reactions by using saturated substrate positive controls. The data obtained was
used in the creation of a glycolytic model which will be discussed in chapter 4.
All the kinetic parameters obtained are compared to the values obtained from the
kinetic study of P. falciparum done by Penkler et al. (2015). The majority of the
kinetic parameters obtained for P. bergheivdiffer to the values for P. falciparum
by a factor between two and four. Differences in the kinetic parameters could be
because of the different enzymatic activities for the two species, but could also be
due to prolonged storage degradation before the experiments were performed. Two
enzymes show noticeable differences to the work of Penkler et al. (2015), namely
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Table 3.11: Enzyme kinetic parameters for P. berghei LDH. The Michaelis constants for
the different metabolites and the maximal velocities of the forward and reverse reaction
that were fitted using the data in figure 3.12 and equation 3.16 are displayed in the table
alongside the values Penkler et al. (2015) fitted or used for P. falciparum. The asymptotic
standard error is given with all the fitted values.
Parameter Fitted Value Literature value
Vf (µmol·min−1·mg−1) 1.35 ± 0.04 2.5 ± 0.1
Vr (µmol·min−1·mg−1) 0.65 ± 0.94 1.4 ± 0.2
Knadh (mM) 0.040 ± 0.006 0.046 ± 0.003
Kpyr (mM) 0.093 ± 0.027 0.13 ± 0.01
Klac (mM) 22 ± 35 3.6 ± 0.3
Knad+ (mM) 0.95 ± 1.15 0.23 ± 0.02
Keq (mM) 11959 150-430
ALD and GAPDH, which will be discussed further in the next chapter.
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Figure 3.12: Results from the kinetic characterization and subsequent equation fitting of P.
berghei lactate dehydrogenase. The velocities of the forward reactions of LDH, measured by
varying the enzyme substrates, (A) NADH and (B) PYR, concentrations is shown with the
velocities of the reverse reaction, measured by varying the enzyme product concentrations,
(C) NAD+ and (D) Lac. Equation 3.16 is fitted to the data set to produce the fitted lines
that describes the data well (adjusted R2 = 1.00).
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Chapter 4
Model construction
4.1 Introduction
Characterizing the kinetic parameters of the different glycolytic enzymes of P.
berghei proved feasible in the previous chapter. To further validate the feasibil-
ity, the creation of a draft metabolic model capable of adequately describing the
flux through the metabolic pathway, would serve as proof that kinetic parameter
characterization is possible.
S v1−−→ X v2−−⇀↽− P (4.1)
Consider reaction 4.1, identical to the reaction use in chapter 3 (eq 3.1. The change
in metabolite, X, could be equated using equation 4.2, which shows that the change
in concentration X over time is due to the velocity of the creation of X from v1
and the consumption of X due to v2. The change in metabolite concentration as
a function of the different enzymes acting on the metabolite is called an ordinary
differential equation (ODE). Combining the ODEs for multiple steps in a system
creates a simplistic understanding of the change in concentration of each interme-
diary metabolite in a system when the kinetic parameters of each step is known
(Dreyer, 1993).
dx
dt
= v1 − v2 (4.2)
The focus of this chapter is to investigate the feasibility of constructing a glycolytic
model of P. berghei. The creation of the model required of a set of ODEs from
the 11 enzymatic steps of glycolysis, a set of starting metabolite concentrations
and the kinetic parameters for all the enzymes catalysing the different reactions.
If the created model is capable of adequately predicting the steady state flux and
metabolite concentration of the system, the construction of a glycolytic model would
prove feasible.
Mathematical analysis, metabolic control analysis, of the enzyme velocities could
lead to a more in depth understanding of the flux through the system as a whole
and control each enzyme has over the flux (Fell and Sauro, 1990). Equation 4.3
demonstrates the classic view of flux control analysis of the system. By perturbing
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the velocity of a reaction, the control the enzyme has over the flux through the
system could be calculated. All the control coefficients for each enzyme equates to
1. The enzyme that constitutes the most control over the system could targeted for
anti-malarial drug development, should the enzyme be sufficiently different to that
of the human orthologue. The rationale for the weakness is that a small decrease in
the function of the enzyme could have devastating effects on the flux through the
whole system and potentially kill the organism.
CJvi =
dLnJ
dLnvi
(4.3)
4.2 Methods
4.2.1 Mathematical modeling
A mathematical model of the glycolytic enzymes measured in chapter 3 was created.
For the creation of the model a set of 12 ordinary differential equations (ODEs) was
created (eqns 4.4 to 4.15) which describe the changes in metabolite concentrations at
a specific time interval. The change in a metabolite concentration are dependent on
the velocity of the creation and removal of the metabolite catalysed by the different
enzymes associated with the metabolite. The velocities of the different enzymes
are described by eqns 4.17 to 4.28 which were discussed in chapter 3. The kinetic
parameters for each of the reactions is summarized in table 3.12 and the starting
concentration of each metabolite is stated in table 4.1. Computational modelling
was done using the NDSolve function of Mathematica version 10.0 and the Time
evolution function of JWS Online (found online at jjj.bio.vu.nl).
g6p′(t) = vHK− vGPI (4.4)
f6p′(t) = vGPI− vPFK (4.5)
f16bp′(t) = vPFK− vALD (4.6)
dhap′(t) = vALD− vTPI (4.7)
gap′(t) = vALD− vGAPDH+ vTPI (4.8)
b13pg′(t) = vGAPDH− vPGK (4.9)
pg3′(t) = vPGK− vPGM (4.10)
pg2′(t) = vPGM− vENO (4.11)
pep′(t) = vENO− vPK (4.12)
pyr′(t) = vPK− vLDH (4.13)
nad′(t) = vLDH− vGAPDH (4.14)
nadh′(t) = vGAPDH− vLDH (4.15)
4.2.2 Constraints, assumptions and conserved moieties
The model is assumed to be a closed system with no compartmentalization and
no export or import of metabolites. Owing to the fact that the transporters have
not been characterized, the change in glucose and lactate concentrations could not
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be described mathematically. The concentrations of glucose and lactate was kept
constant at the model starting concentrations. The kinetics of ATPase were not
measured, requiring the use of constant ATP and ADP concentrations. NADH and
NAD+ concentration is considered to be in conserved moiety defined as the total
concentration of the two metabolites would always add up to the same concentration,
described in eq 4.16.
NADtotal = NAD+ +NADH (4.16)
Table 4.1: Starting concentrations (mM) for the different fixed and variable metabolites
used for model creation.
Metabolite Concentration (mM)
G6P 0.028
F6P 0.28
F16BP 0.28
DHAP 0.28
GAP 0.28
B13BP 0.28
PG3 0.28
PG2 0.28
PEP 2.8
Pyr 2.8
NAD+ 0.7
NADH 0.3
Glu* 5.0
Lac* 0.1
ADP* 0.5
ATP* 1.5
4.2.3 Model analysis
Steady state concentrations for the variable metabolites and steady state enzyme
fluxes were calculated using the FindRoot function of Mathematica version 10.0.
The flux control matrix of the model was created and calculated using the Flux
control matrix function from JWS Online (found online at jjj.bio.vu.nl).
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4.3 Results and Discussion
A mathematical model of the glycolytic pathway was constructed using the NDSolve
function of Mathematica version 10.0. For the construction of the model, a set of
ordinary differential equations was used (eqns 4.4 to 4.15) that described the change
for each variable metabolite in the glycolytic pathway according to the velocities of
each glycolytic enzyme (eqns 4.17 to 4.28) that was bound by the kinetic parameters
measured in chapter 3 (table 3.12) and the starting metabolite concentrations (table
4.1).
Figure 4.1 shows the change of each of the variable metabolites concentration
per time iteration as a time course of the model presented by JWS. Only after 2500
time iterations did the model reach a stable steady state, thus requiring further
analysis. Modelling with Mathematica version 10.0 delivered similar results (figure
C.-1) which, because of the size of the graphical representation of the flux, is dispayed
in appendix C. Steady state concentration for the different metabolites of the draft
model is displayed next to the time course, 4.1. As observed from the velocities of
the initial model, the concentration for F16BP far exceeds biological concentrations;
also reflected by examining the steady state metabolite concentrations (figure 4.1).
It appears that the initial model failed, but JWS allowed this researcher to create
a metabolic control analysis heat map (figure 4.2) to interpret the control each
glycolytic enzyme had on the flux of the model. The darker the bands are on figure
4.2, the greater the control the specific enzyme has on the flux as a whole. Results
from the flux control analysis indicated that GAPDH and aldolase had the greatest
control (78.3%) over the whole model. As previously discussed in the results from
chapter 3, the two enzymes had the greatest difference in Vf ’s compared to the work
of Penkler et al. (2015).
Figure 4.1: Metabolite concentrations for model over time course from JWS Online and
steady state concentrations. The different glycolytic intermediate metabolites are shown
as a function of time iterations (minutes) and the metabolite steady state concentrations
shown on the bar graph on the right. The equations and enzyme kinetic parameters are
described in text. The concentration of F16BP does not reach a steady state in 10 time
iterations and the concentration increases beyond physiological conditions. The model does
not accurately describe the change of intermediate metabolites for the different P. berghei
glycolytic enzymes
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Figure 4.2: A heat map created by JWS online that shows the difference in relative flux
control the different enzymes have on the glycolytic model using the concentration control
matrix function. The band shade intensity indicates the relative percentage control the
enzyme has on the flux of the system. Aldolase and GAPDH seems to have majority control
over the flux through the system and would explain the concentrations of the metabolites
that fall outside of biological standards in table 4.2
Since this particular project is focussed on the feasibility of creating a full and
accurate model, the model was reconstructed with the maximal velocities for aldolase
and GAPDH from the work of Penkler et al. (2015), rather than the fitted values
obtained from the characterization of the different enzymes, using JWS online and
Mathematica (figure 4.3). The recreated model reaches steady state in fewer time
iterations compared to that of the previous model with steady concentrations that
closer reflect that of biological possible conditions (table 4.2 and bar graph on figure
4.3). The flux for each enzyme and steady state concentrations are given for both
models in table 4.2 and 4.3. Steady state flux of the new model is 4 times greater than
the flux of the original model and the combined control aldolase and GAPDH have
over the system flux decreased to 30%. Flux values from Penkler et al. (2015)(0.265
and 0.509) are 6 times greater than the flux values obtained for P. berghei.
Creation of a working model required a few assumptions that included the com-
plete conversion of glucose to lactate and no influence of auxiliary pathways, for
example the pentose or glycerol pathway. Some metabolites, including ATP, ADP,
Glu and Lactate, were constrained to specific concentrations, which reflect biologi-
cal conditions, but the true steady state concentrations of these metabolites is not
known. The entire model is placed in one uniform compartment; but this does not
hold true for biological life, as certain pathways are compartmentalised, but for the
purpose of creating the model, one uniform compartment is sufficient.
4.3.1 Summary
Creation of a working model appears to be feasible and worth further investigation
and improvement. The draft model was altered to use the Vf values for Aldolase
and GAPDH from the work of Penkler et al. (2015) and the model reached adequate
steady state within acceptable biological steady state concentrations. A complete
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Figure 4.3: Metabolite concentrations for the corrected model over time course from JWS
Online and steady state concentrations. The different glycolytic intermediate metabolites
are shown as a function of time iterations and the steady state metabolite concentrations
on the bar graph on the right. The equations and enzyme kinetic parameters are described
in text. The concentrations of the intermediate metabolites, summarized in table 4.2, fall
within the physiological range. The model reaches steady state faster than the previous
model.
Table 4.2: Model steady state metabolites concentrations. The variable metabolite con-
centrations of the first and corrected model are displayed below. The concentrations (mM)
were calculated using Mathematica’s find root function.
Metabolite Steady state concentrationof the glycolytic model (mM)
Steady state concentration of
the recreated glycolytic model (mM)
G6P 7.28 0.94
F6P 3.51 0.40
F16BP 488 5.0
DHAP 23.9 9.0
GAP 1.88 0.59
B13PG 4.73× 10−4 4.88× 10−3
PG3 0.44 0.33
PG2 0.051 0.23
PEP 0.16 0.48
Pyr 5.50 2.14
NAD+ 1.00 1.00
NADH 1.08× 10−3 5.06× 10−3
working model will require a complete characterization of the glycolytic enzymes
that could be achieved with multiple repeats of the characterization with different
P. berghei extracts. Validation of the glycolytic model will also be necessary to
prove that the glycolytic model could adequately describe the glucose flux through
the parasite; both for the intact parasite and the infected red blood cell. The model
will also need to be expanded to include the glucose, lactate, glycerol, pyruvate
transporters and the kinetic characterization of the RBCs enzymes, along with ap-
propriate compartmentalization and auxiliary pathways, to create a network-level
P. berghei model.
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Table 4.3: Flux (µmol·min−1·mg−1) of the different enzymes for both the first and cor-
rected glycolytic model. The fluxes were calculate using Mathematica’s NDSolve function.
Enzyme Steady state flux of theglycolytic model(µmol·min−1·mg−1)
Steady state flux of the
corrected glycolytic
model(µmol·min−1·mg−1)
HK 0.0087 0.038
GPI 0.0087 0.038
PFK 0.0087 0.038
ALD 0.0087 0.038
TPI 0.0087 0.038
GAPDH 0.017 0.075
PGK 0.017 0.075
PGM 0.017 0.075
ENO 0.017 0.075
PK 0.017 0.075
LDH 0.017 0.075
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Chapter 5
General discussion, future work
and conclusion
The goal of this project was to evaluate the feasibility of constructing a whole body
rat model infected with P. berghei. Analysing the feasibility required the acquisition
of blood and kinetic parameters, the creating of a preliminary model to assess if the
metabolic data could be measured and mathematically described using a molecular
and systems biology approach. Four objectives were set: First, we had to inoculate
rats with P. berghei and be able to obtain blood parameters, including blood glucose,
lactate, haematocrit and parasitemia, over the course of the infection. The blood
glucose and lactate homeostatis of the rats were then perturbed to assess if it is
possible to measure homeostatic potential. Should measuring the blood parameters
be possible, the possibility of constructing a whole body model that could describe
the changes over the course of the infection would be investigated. The second
and third objectives focussed on the prospect of isolating intact parasites and the
enzymes contained in the parasite to quantify the kinetic parameter of each enzyme.
Lastly, the fourth objective was to construct a working glycolytic model with the
kinetic parameters obtained from the kinetic studies
In chapter 2, "Rat blood analysis", we demonstrated that it is possible to in-
oculate rats with P. berghei, ANKA strain, and obtain blood parameters from the
rats. Microscopy and enzymatic glucose and lactate determination proved to be
reliable and accurate methods to measure these blood parameters. Further im-
provements in the methodology need to be implemented for more accurate glucose
and lactate concentration measurement as large variability was found for the con-
centrations. Reasons for the variability could be because of the panicked state of
the rats resulting in agitation and spikes in the lactate concentrations. Methods
to improve the accuracy of the blood parameter data collection includes anaesthe-
sia of the rats during all blood collection experiments and environmental changes
to keep the animals calm. Rat subjects could also be calmed inducing tolerance
to handling a month prior to the experiments. The growth of the parasites and
decrease in haematocrit displayed predictable patterns, allowing us to quantify the
relationship between haematocrit and parasitemia. Although the measuring of the
blood glucose and lactate concentrations proved possible, the results obtained from
the pulse experiments and the lactate concentration determination did not present
66
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with a distinct pattern and therefore, measuring of the blood changes needs to be
repeated and the mechanism of homeostasis investigated in more detail.
Isolation of the parasites, isolation of the glycolytic enzymes from sufficient
biomass and kinetic parameter quantification proved practicable. In chapter 3, all
the glycolytic enzymes of P. berghei were characterized in terms of their Km’s,
Vmax’s and Keq’s. The results of the enzymatic characterizations were compared
to the enzymatic parameters P. falciparum characterized by Penkler et al. (2015),
which showed some similarities. The maximal velocities of GAPDH and ALD are
significantly lower than that of Penkler et al. (2015), indicating the need for im-
provement of the experimental design. Due to limitations in the amount of biologi-
cal samples available, the limited data points of the kinetic characterization forestall
the publication the kinetic parameters, necessitating refinements and repeating of
the work.
With the kinetic parameters obtained in chapter 3, a glycolytic model was cre-
ated to assess the feasibility of constructing a model that could adequately describe
the flux through P. berghei glycolysis in chapter 4. The feasibility of constructing
the model depends on the ability of the model to predict steady state metabolite
concentrations that reflect the intercellular metabolite concentrations of the para-
site. The first attempt at constructing a model using the experimentally obtained
kinetic parameters did not satisfactory predict the steady state concentrations and
flux. Using MCA, the enzymes with the most control over the system, ALD and
GAPDH, were identified. Since the project is focussed on the feasibility of con-
structing a model and not about the construction of a flawless model, the kinetic
parameters of ALD and GAPDH from the work of Penkler et al. (2015) were used
for the construction of a revised model. Near physiological steady state concentra-
tions were predicted by the revised model, proving that the construction of a model
is feasible. Perfecting the kinetic parameter quantification will lead to an increased
precision of the model.
Various strategies could be implemented to improve our knowledge of the pre-
liminary model and the metabolism of a rat infected with P. berghei: Respiratory
changes of rats infected with malaria could be modelled using a metabolic chamber
for the rats that calculates the oxygen consumption by measuring the the carbon
dioxide formation; the internal lactate uptake of the body could be better under-
stood by attaching lactate biosensors to the liver of the rats; in vitro cultivation
of the parasite would allow for validations of the model by measuring the flux and
comparing it to the model predicted values; expansion of the model by including the
metabolism, transporters and compartmentalization of the RBC and the auxiliary
pathways of the parasite and the flux obtained from the glycolytic model could be
validated by measuring the glucose consumption and lactate production of intact
parasites.
In conclusion, the aims and objectives of the project have been met;
a summation follows:. The rats were infected with P. berghei and the blood
parameters were measured. Relationships between the different parameters and
parasitemia were also investigated. Measuring the homeostatic potential of the rat’s
metabolism proved to be possible for the glucose pulse experiments, but not for
the lactate pulse experiment. Since no differences could be measured between the
infected and non-infected glucose pulse experiments, quantification of the effect the
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infection has on the homeostatic potential could not be performed. However limited
the quantification of the relationships and homeostatic potential, the determination
of the different parameters gives evidence enough to assume that the body model
is feasible. Furthermore, the characterization of the glycolytic enzymes displayed
similar results to that of the work of Penkler et al. (2015), giving rise to the assump-
tion that creating a glycolytic model is practicable. A glycolytic model was then
successfully constructed, capable of predicted steady-state metabolic concentrations
that fall within biological ranges. Although the accuracy of the model could only be
validated by comparing the flux of the model to the glucose flux of intact parasites,
the successful construction of the model proves that glycolytic model construction is
possible, but incomplete, for no validations were performed. From the above men-
tioned, the project demonstrated that, with the combination of molecular biology
and systems biology, the creation of a whole body model that could describe hypo-
glycemia and lactic acidosis in rats infected with P. berghei is feasible, warranting
further investigation. Once the whole metabolism of the parasite is characterized,
the progression from single parasite modelling to the creation of a whole body would
need to include the effect of parasitemia and the homoeostatic capabilities of the
rats to a functional model. Many challenges exist when working with P. berghei,
including extreme difficulties with in vitro culturing of the parasite, which could
be circumvented if another organism, for example P. knowlesi, is used. It should
be noted that, although the feasibility of completing such a model is clear, it is
not known whether or not the data obtained is accurate as limited repeats of some
experiments were performed.
With the creation of a whole body model, a weakness could be identified in the
malarial parasite using metabolic control analysis. Once a weakness is discovered,
effects of inhibition of the enzyme could be predicted with the model. Use of the
model could be extended to serve as a powerful diagnostic tool, as extent of the
infection could be calculated if one or more of the blood parameters are known.
The promise of high throughput drug development derived from the understanding
of the host-parasite interaction on a metabolic level gives reason for the pursuit of
creating of a full model for malarial infections and other infectious diseases.
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Appendix A
Buffers and Media Composition
Table A.1: Enzyme Assay Buffer (EAB). The components, final concentrations and com-
panies from which the compound were purchased. pH adjusted to final pH of 7.17
Final Concentration Compound Company
20 mM HEPES Sigma-Aldrich
20 mM Magnesium Chloride Hexahydrate Merck
10 mM Potasium Chloride Merck
20 mM Sodium Chloride Merck
Table A.2: Culture Media (CM). The components, final concentrations and companies
from which the compound were purchased. pH adjusted to final pH of 7.25
Final Concentration Compound Company
10.4 g/L RPMI-1640 medium Simga-aldrich
4 g/L Glucose Merck
5 g/L Albumax II Thermo Fisher Scientific
2.1 g/L Sodium Bicarbonate Simga-aldrich
0.4 g/L Hypoxanthine Simga-aldrich
0.05 g/L Gentamycin Sulphate Salt Simga-aldrich
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Table A.3: Glu-Lac-Determination Buffer (GLDB). The components, final concentrations
and companies from which the compound were purchased. pH adjusted to final pH of 7.6
Final Concentration Compound Company
150 mM HEPES Sigma-aldrich
15 mM Magnesium Sulphate Heptahydrate Merck
3.75 %v/v Hydrazine monohydrate* Sigma-aldrich
*Hydrazine monohydrate is only added to the Lactate determination buffer and not
the Glucose determination buffer
Table A.4: Citrate–phosphate–dextrose–adenine (CPDA) adjusted from Kurup et al.
(2004). The components, final concentrations and companies from which the compound
were purchased. pH adjusted to final pH of 7.6
Final Concentration Compound Company
15.2 mM Citric acid Merck
87.6 mM Sodium citrate anhydrous Saarchem
1.98 mM Adenine Calbiochem
1.8 mM L-ascorbic acid Sigma-aldich
4.4 mM Nicotinic acid Sigma-aldich
15.8 mM Sodium dihydrogen phosphate Merck
173 mM Dextrose Merck
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Appendix B
Full Rat Blood Analysis Data
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Figure B.1: Full parasitemia measurements. (A)Average parasitemia per day. (B)Log of
average parasitemia per day
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Figure B.2: Full haematocrit measurements. (A)Average haematocrit per day.
(B)Haematocrit per log average parasitemia
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Figure B.3: Full blood glucose and lactate per parasitemia. (A)Blood lactate (mM) per
parasitemia. (B)Blood Glucose (mM) per parasitemia.
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Figure B.4: Full average blood glucose and lactate per day. (A)Average blood Lactate
(mM) per day. (B)Average blood Glucose (mM) per day.
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Appendix C
Full model fluxes
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Figure C.-1: Metabolite concentrations of the model over time from Mathematica 10.0.
Different substrate concentrations over time as simulated by a computer for the different
kinetic parameters and enzyme characteristics. From (A) to (L) the substrates at specific
time point include G6P, F6P, F16BP, DHAP, GAP, B13PG, PG3, PG2, PEP, PYR, NAD+,
NADH respectively. The equations and parameters used for the creation of the model are
described in text. The time course extents past 2000 time iterations (minutes) to reach
steady state
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